In-Depth Analysis Of Metabolic Phenotype By Studying Age- And Sex-Related Features Of Type 2 Diabetes by Carbo Meix, Anna <1994>
Alma Mater Studiorum – Università di Bologna 
 
DOTTORATO DI RICERCA IN  
ONCOLOGIA, EMATOLOGIA E PATOLOGIA 
Ciclo XXXIII 
 
Settore Concorsuale: 06/A2 




In-Depth Analysis Of Metabolic Phenotype By Studying Age- 
And Sex-Related Features Of Type 2 Diabetes 
 
 
Presentata da: Anna Carbó Meix 
 
Coordinatore Dottorato        Supervisore         Co-supervisore 
 
Prof.ssa           Prof.                                   Prof.  
Manuela Ferracin         Stefano Salvioli                 Paolo Garagnani 
  
 




LIST OF FIGURES ..................................................................................................................... 4 
LIST OF TABLES ....................................................................................................................... 6 
LIST OF ABBREVIATIONS ...................................................................................................... 8 
ACKNOWLEDGEMENTS ....................................................................................................... 12 
ABSTRACT ............................................................................................................................... 13 
INTRODUCTION ..................................................................................................................... 14 
1. TYPE 2 DIABETES ......................................................................................................................... 14 
1. Overview ....................................................................................................................................... 14 
2. Epidemiology ................................................................................................................................ 14 
3. Genetics......................................................................................................................................... 14 
4. Diagnosis ....................................................................................................................................... 15 
5. Motivation ..................................................................................................................................... 15 
2. ATHEROGENIC DYSLIPIDEMIA ................................................................................................ 16 
6. Lipoproteins (LDL, VLDL, HDL), Cholesterol, Triglycerides and Apolipoproteins......................... 16 
7. Common risk factors in cardiovascular disease and type 2 diabetes ................................................. 19 
8. Thrombosis and fibrinolysis ........................................................................................................... 20 
3. GLYCANS ....................................................................................................................................... 21 
9. Glycans definition .......................................................................................................................... 21 
10. Glycans biosynthesis ...................................................................................................................... 21 
11. Molecular diversity of glycans ....................................................................................................... 23 
12. Functions of glycans ...................................................................................................................... 23 
13. Genetics of protein glycosylation ................................................................................................... 24 
14. Environmental factors affecting protein glycosylation ..................................................................... 25 
MATERIALS & METHODS .................................................................................................... 26 
15. Data description ............................................................................................................................. 26 
16. Preprocessing: Clinical Database and N-glycans ............................................................................. 31 
17. Cohorts: controls, prediabetics, diabetics ........................................................................................ 36 
CHAPTER 1: CHARACTERIZATION OF THE T2D-DYSMETABOLIC-AGING 
PHENOTYPE ............................................................................................................................ 37 
4. INTRODUCTION ............................................................................................................................ 37 
18. Intracellular biological roles of glycans: focus on cellular metabolism ............................................ 38 
19. Extracellular biological roles of glycans: focus on inflammation (IgG glycosylation) ...................... 44 
3 
 
20. N-glycans as biomarkers in liver diseases, aging, and age-related diseases ...................................... 46 
5. MATERIALS AND METHODS ...................................................................................................... 54 
PART I ....................................................................................................................................... 55 
6. AIMS ................................................................................................................................................ 55 
7. RESULTS ......................................................................................................................................... 56 
21. Demographic characteristics of the cohort ...................................................................................... 56 
22. Prediction of (non-)diabetic status by HbA1c and by N-glycans ...................................................... 59 
23. Visualization of mean values and integrated weights....................................................................... 67 
PART II ...................................................................................................................................... 85 
8. AIM .................................................................................................................................................. 85 
9. RESULTS ......................................................................................................................................... 86 
24. Sources of variation in Phenomics, T2D, Lipids, Liver, Kidney, Iron, Coagulation, Blood & 
Glycomics data sets ................................................................................................................................ 86 
10. DISCUSSION ............................................................................................................................... 93 
CHAPTER 2: ESTIMATION OF AN INNOVATIVE COMPOSITE AGING CLOCK  AS 
BIOMARKER FOR TYPE 2 DIABETES AND RELATED METABOLIC PHENOTYPES 95 
11. INTRODUCTION........................................................................................................................ 95 
25. Molecular biomarkers of aging ....................................................................................................... 96 
26. Phenotypical biomarkers of aging ................................................................................................. 100 
27. Motivation ................................................................................................................................... 101 
12. MATERIALS AND METHODS ............................................................................................... 101 
28. Materials...................................................................................................................................... 101 
29. Methods....................................................................................................................................... 101 
13. AIM ............................................................................................................................................ 103 
14. RESULTS................................................................................................................................... 104 
30. Univariate regression models: Age ~ Variable .............................................................................. 104 
31. Statistical models ......................................................................................................................... 105 
32. Association between “Biological Age” and “Chronological Age”, separately in sexes: .................. 107 
33. Association between “Biological Age” with disease (T2D) separately in sexes: ............................. 108 
34. Associations with continuous traits or N-glycans: Trait/N-glycan ~ Phenotypical Age + Age + Sex + 
Group................................................................................................................................................... 109 






LIST OF FIGURES  
Figure 1. Plasma lipid exchange. ................................................................................................................. 17 
Figure 2. Association between BMI and T2D .............................................................................................. 19 
Figure 3. Relative risk of CVD in normoglycemia, prediabetes and diabetes ................................................ 20 
Figure 4. Examples of glycans (IUPAC Gold Book) .................................................................................... 21 
Figure 5. Protein N-glycosylation biosynthesis ............................................................................................ 22 
Figure 6. O-GlcNAcylation in cell metabolism ............................................................................................ 23 
Figure 7. Biological roles of glycans proposed by Varki (2017) ................................................................... 24 
Figure 8. Distribution of N-glycans without vs without clr transformation ................................................... 32 
Figure 9. Distribution of Blood Cells without vs without clr transformation ................................................. 33 
Figure 10. Metaflammation intra-organ crosstalk ........................................................................................ 38 
Figure 11. Metaflammation inter-organ crosstalk ........................................................................................ 39 
Figure 12. Metaflammation intracellular crosstalk ....................................................................................... 39 
Figure 13. O-GlcNAcylation in conditions of hyperglycaemia ..................................................................... 40 
Figure 14. Relationship between chronic glycaemia, chronic glycosylation and insulin sensitivity ............... 41 
Figure 15. Hyperglycaemia, glycosylation and cardiovascular disease ......................................................... 41 
Figure 16. The absence of glycosylation of Glut2 in mice fed with high fat diet impairs insulin secretion ..... 42 
Figure 17. Inflammasomes activation in glucotoxicity/lipotoxicity .............................................................. 42 
Figure 18. Endoplasmic reticulum stress responses...................................................................................... 43 
Figure 19. Antibody glycosylation controls antibody activity....................................................................... 44 
Figure 20. What comes first in RA, HIV and metabolic syndrome, disease or inflammation? ....................... 45 
Figure 21. The relationship between AGEs and T2D/obesity ....................................................................... 46 
Figure 22. Glycosyltransferases enzymes .................................................................................................... 47 
Figure 23. Summary of main findings regarding alteration of glycosylation in liver pathologies ................... 47 
Figure 24. Two-way orthogonal partial least squares algorithm.................................................................... 54 
Figure 25. Decomposed parts of the O2PLS integrations between 44 clinical variables and 10 N-glycans in 
four different age ranges by groups and sexes ............................................................................................. 60 
Figure 26. Joint PC1 loading values of control males aged 20-85 y. ............................................................. 61 
Figure 27. Joint PC1 loading values of control females aged 20-85 y. .......................................................... 62 
5 
 
Figure 28. Joint PC1 loading values of prediabetic males aged 20-85 y. ....................................................... 63 
Figure 29. Joint PC1 loading values of prediabetic females aged 20-85 y. .................................................... 64 
Figure 30. Joint PC1 loading values of diabetic males aged 20-85 y. ............................................................ 65 
Figure 31. Joint PC1 loading values of diabetic females aged 20-85 y. ......................................................... 66 
Figure 32. Parallel plots of groups of variables (I) ....................................................................................... 67 
Figure 33. Parallel plots of groups of variables (II) ...................................................................................... 68 
Figure 34. Means and weights of fasting glucose ......................................................................................... 68 
Figure 35. Means and weights of glycated haemoglobin .............................................................................. 69 
Figure 36. Means and weights of HOMA .................................................................................................... 69 
Figure 37. Means and weights of fasting insulin .......................................................................................... 70 
Figure 38. Means and weights of BMI ........................................................................................................ 70 
Figure 39. Means and weights of WHR ....................................................................................................... 70 
Figure 40. Means and weights of total cholesterol ....................................................................................... 71 
Figure 41. Means and weights of LDL ........................................................................................................ 71 
Figure 42. Means and weights of HDL ........................................................................................................ 72 
Figure 43. Means and weights of triglycerides ............................................................................................. 72 
Figure 44. Means and weights of alkaline phosphatase ................................................................................ 73 
Figure 45. Means and weights of total bilirubin ........................................................................................... 73 
Figure 46. Means and weights of AST ........................................................................................................ 74 
Figure 47. Means and weights of C reactive protein .................................................................................... 74 
Figure 48. Means and weights of creatinine ................................................................................................. 75 
Figure 49. Means and weights of azotemia .................................................................................................. 75 
Figure 50. Means and weights of uric acid .................................................................................................. 76 
Figure 51. Means and weights of ferritin. .................................................................................................... 76 
Figure 52. Means and weights of fibrinogen ................................................................................................ 77 
Figure 53. Means and weights of haemoglobin ............................................................................................ 78 
Figure 54. Means and weights of white cells ............................................................................................... 78 
Figure 55. Means and weights of platelets ................................................................................................... 79 
Figure 56. Means and weights of telomere length ........................................................................................ 79 
Figure 57. Means and weights of GP1 ......................................................................................................... 80 
Figure 58. Means and weights of GP2 ......................................................................................................... 80 
6 
 
Figure 59. Means and weights of GP3 ......................................................................................................... 81 
Figure 60. Means and weights of GP4 ......................................................................................................... 81 
Figure 61. Means and weights of GP5 ......................................................................................................... 82 
Figure 62. Means and weights of GP6 ......................................................................................................... 82 
Figure 63. Means and weights of GP7 ......................................................................................................... 83 
Figure 64. Means and weights of GP8 ......................................................................................................... 83 
Figure 65. Means and weights of GP9 ......................................................................................................... 84 
Figure 66. Means and weights of GP10 ....................................................................................................... 84 
Figure 67. Decomposed parts of the O2PLS integrations between 8 different data sets and 10 N-glycans in 
four different age ranges and the total age range by groups and sexes .......................................................... 86 
Figure 68. Pearson inter-correlations among the joint PCs in Ctrl M ............................................................ 88 
Figure 69. Pearson inter-correlations among the joint PCs in Ctrl F ............................................................. 89 
Figure 70. Pearson inter-correlations among the joint PCs in PreDiab M ..................................................... 89 
Figure 71. Pearson inter-correlations among the joint PCs in PreDiab F ....................................................... 90 
Figure 72. Pearson inter-correlations among the joint PCs in Diab M........................................................... 90 
Figure 73. Pearson inter-correlations among the joint PCs in Diab F ............................................................ 91 
Figure 74. Age acceleration among controls, prediabetics, and diabetics in both sexes ............................... 108 
LIST OF TABLES 
Table 1. Database classified variables by biomedical groups........................................................................ 26 
Table 2. 10 N-glycans obtained with the DSA-FACE (images obtained with the Glycoworkbench software) 30 
Table 3. Summary of the major glycomic signatures of T2D described in literature...................................... 49 
Table 4. Summary of the major glycomic signatures of aging described in literature .................................... 52 
Table 5. Patients baseline characteristics ..................................................................................................... 56 
Table 6. Number and frequency of individuals that are affected by clinical conditions ................................. 58 
Table 7. Number and frequency of individuals that take medication............................................................. 58 
Table 8. Confusion matrix for HbA1c ......................................................................................................... 59 
Table 9. Confusion matrix for 10 N-glycans ................................................................................................ 59 
Table 10. Sample size of groups by age ranges and in the full age range and frequency of individuals in each 
age range per group .................................................................................................................................... 60 
Table 11. Top 10 joint PC1 loading values of phenomics and glycomics data sets in Ctrl M ......................... 61 
Table 12. Top 10 joint PC1 loading values of phenomics and glycomics data sets in Ctrl F .......................... 62 
7 
 
Table 13. Top 10 joint PC1 loading values of phenomics and glycomics data sets in PreDiab M .................. 63 
Table 14. Top 10 joint PC1 loading values of phenomics and glycomics data sets in PreDiab F ................... 64 
Table 15. Top 10 joint PC1 loading values of phenomics and glycomics data sets in Diab M ....................... 65 
Table 16. Top 10 joint PC1 loading values of phenomics and glycomics data sets in Diab F ........................ 66 
Table 17. Pearson intra-correlations between pairs of Phenomics/Glycomics joint scores ............................. 67 
Table 18. Pearson intra-correlations of the joint PC scores in each pair of integrated data sets ...................... 87 
Table 19. Top 4 loading values of the joint parts for each pair of integrated data sets ................................... 91 
Table 20. Univariate regression models. P-value was adjusted for multiple comparisons with Benjamini-
Hochberg correction at α=0.05 .................................................................................................................. 104 
Table 21. Best combination of hyperparameters calculated with cross-validation ....................................... 106 
Table 22. Metrics of model performance ................................................................................................... 106 
Table 23. Summary output of the linear model: Predicted Age = Biological Age ~ Chronological Age ....... 107 
Table 24. Summary output of the multinomial logistic model: Group (Ctrl vs PreDiab/Diab) ~ Biological Age
 ................................................................................................................................................................ 108 
Table 25. Pairwise comparisons using Wilcoxon’s rank sum test in KDM. P-value adjustment method: 
Benjamini-Hochberg. P<0.05 (*), p<0.01 (**), p<0.001 (***) at α=0.05.................................................... 109 
Table 26. Association between continuous N-glycans species and Biological Age, Chronological Age, Sex 
and Disease Status: Trait ~ Biological Age + Chronological Age + Disease Status ..................................... 109 
Table 27. Association between continuous clinical traits and Biological Age, Chronological Age, Sex and 















LIST OF ABBREVIATIONS 
AD: Alzheimer’s disease 
ADA: American Diabetes Association 
ADCC: antibody-dependent cellular cytotoxic 
ADMA: asymmetric dimethylarginine 
AFAR: American Federation for Aging Research 
Age acceleration: AgeAccel 
AGE: advanced glycated end product 
ALD: alcoholic liver disease 
ALE: advanced lipoxidation end product 
AMPK: AMP-activated protein kinase 
Apo: apolipoprotein  
ASAH1: lysosomal enzyme 
AT: adipose tissue 
ATP: adult treatment panel 
AUC: area under the curve 
BMI: body mass index 
CAD: coronary artery disease 
CCP: anti-citrullinated antibodies 
CDG: congenital disorders of glycosylation 
CETP: cholesteryl ester transfer protein  
CHD: cardiovascular heart disease 
CI: confidence intervals 
Clr: center-log ratio  
CM: chylomicrons 
CRP: C reactive protein 
CVD: cardiovascular disorders 
DAMP: damage-associated molecular pattern 
DDP-4: dipeptidyl peptidase 4 
DNA methylation: DNAm 
9 
 
DSA-FACE: DNA sequencer-aided fluorophore-assisted carbohydrate electrophoresis 
EC: endocannabinoids 
EDA: exploratory data analysis 
EGFR: estimated glomerular filtration rate 
EN: elastic net regression 
ER: endoplasmic reticulum 
FEV1: forced expiratory volume in one second 
FFA: free fatty acids 
Galectin9: Gal9 
GFAT: glutamine-fructose-6-phosphate transaminase 
GGT: gamma glutamyl transpeptidase 
GP: glycan peaks  
GWAS: genome-wide association studies 
HbA1c: glycated haemoglobin 
HBP: hexosamine biosynthetic pathway 
HIV: human immunodeficiency virus 
HMGB1: high mobility group box 1 
HTP: high-throughput 
IAPP: Islet Amyloid Polypeptide 
IDF: International Diabetes Federation 
IDL: intermediate density lipoprotein 
IFG: impaired fasting glucose 
Ig: immunoglobulin 
IGT: impaired glucose tolerance 
IKK2: Inhibitor kappa B kinase 2 
IL: interleukin 
IR: insulin receptor 
IR: insulin receptor 
ISR: insulin receptor substrate  
KDM: Klemera-Doubal method  
10 
 
K-S: Kolmogorov-Smirnov test 
LAL: lysosomal acid lipase 
LDL: Low density lipoprotein 
LDL-C: low density cholesterol 
LLFS: Long Life Family Study 
LPS: lipopolysaccharide  
MAD: mean absolute deviations 
MCP-1: monocyte chemoattractant protein 
MS: mass spectrometry 
MetS: metabolic syndrome 
MSE: mean-squared error 
mTOR: mammalian target of rapamycin  
NA: missing value(s) 
NHANES: National Health and Nutrition Examination Survey 
NLRP3: NLR family pyrin domain containing 3 
O2PLS: two-way orthogonal partial least squares  
O-GlcNAc: O-linked β-N-acetylglucosamine 
O-GlcNAcylation: O-GlcNAc modification 
OOB: out-of-bag 
OR: odds ratio 
P.LRC: platelet large cell ratio 
PC: principal components 
PCA: principal component analysis 
PD: Parkinson’s disease 
PI3K: phosphatidylinositol-3-kinase 
PKC: protein kinase C 
PTP1B: protein tyrosine phosphatase 1B 
R2: correlation 
RA: rheumatoid arthritis 
RDW-CV: red blood cell distribution width – coefficient of variation 
11 
 
RNA: ribonucleic acid 
ROS: reactive oxygen species 
RR: relative risk 
RR: ridge regression 
S6K1: S6 kinase 1 
SAMPs: self-associated molecular patterns 
SDMA: symmetric dimethylarginine 
SNP: single nucleotide polymorphism 
SOCS3: suppressor of cytokine signaling 3 
SVM: support vector machine 
SVR: support vector regression 
T1D: type 1 diabetes 
T2D: Type 2 diabetes  
T2DM: Type 2 diabetes mellitus  
TAFI: thrombin-activatable fibrinolysis inhibitor  
TG: triglycerides 
TNF-α: tumor necrosis factor-1 
TSC1/2: tuberous sclerosis 1/2 
TXNIP: thioredoxin interacting protein 
U: transformed units 
VLDL: very low density lipoprotein 
WC: waist circumference 
WHR: waist-to-hip ratio 








I would like to express my gratitude to everybody who helped me during the course of the PhD. 
I would like to thank Claudia Sala and Cristina Giuliani for having introduced me to statistics and R 
programming and genetics, respectively. I would like to thank Maria Giulia Bacalini for her 
mentorship and feedback during my PhD closure and thesis writing. I would also like to thank 
Stefano Salvioli for the useful comments on PhD reports and thesis. 
I would like to specially thank Noémie Génsous for her availability and help when I needed, as well 
as to Francesco Ravaioli, and Kat Kwiatkowska Malgorzata for hanging out some evenings.  
Especial thanks to the colleagues from the IMforFUTURE project for sharing both science and fun. 
At the scientific level, I would like to thank: Shafiq for showing me different software for post-
genomic analysis; Maarten, for helping me with code by simulating data; Arianna Landini, for her 
time and willingness to show me how to perform a GWAS; Tamás, for showing me a software for 
designing glycans; Iva, for the many discussions and shared beers, as well as for the help with the 
server; Zhujie, for helping me with the questions coming up, and Azra, for sharing information 
about glycans normalization methods. I thank Samira, Frania and Annah for the shared enjoyment 
during meetings. 
I also would like to thank Hae-Won Uh, Zhujie Gu and Said el Bouhaddani for welcoming me at 
UMCU, and for the guidance and feedback for my analysis. 
Per suposat, vull agrair el suport incondicional en tot de mons pares, Santi i Maria José, sense el 
qual no hauria arribat mai fins aquí. Vull donar també les gràcies a Míriam, el millor regal que mai 
m’han fet els meus pares, pel suport i la confiança durant aquests anys difícils de doctorat. També 
vull agrair als familiars que van contribuir que la meva estada a Bolonya fos possible: iaies Pepita i 
Neus, tiets Hilde i Pepi, Jordi i Tere, moltes gràcies. I voldria manifestar també el meu agraïment a 
les ties, Imma i Maribel, pel seu suport, així com a la resta de la família. 
Per ultimo ma non meno importante, voglio ringraziare a Paolo Garagnani il suporto a livello 
scientifico ed emozionale, per cui senza non avrei finito il dottorato. “La vita è complicata…” La 
vita è la intensità di luce che scegliamo portare ad ogni posto ad ogni istante. Grazie per esserne 











Type 2 diabetes mellitus (T2DM) is an age-related disease characterized by chronic hyperglycaemia 
mainly explained by insulin resistance and impaired insulin secretion and strongly linked to 
dysregulation of carbohydrate, lipid and protein metabolism. T2DM is a worldwide increasing 
disabling disease – in 2013, the International Diabetes Federation estimated that 382 million adults 
suffered from T2DM and that by 2035 there will be 592 people affected. These worrisome numbers 
challenge biomedical research at identifying new biomarkers for the diagnosis. The purpose of this 
study was to analyse and integrate different sources of phenomics (clinical) data – clinical history, 
anthropometrical measurements, biochemical parameters, cell counts and blood differential, and 
medication – with glycomics data in control, prediabetics and diabetics cohorts, in order to 1) 
identify the major sources of variation in both data sets, 2) visualize trends or patterns in variables 
within- and between-omics (e.g. a combination of N-glycans highly correlated with some 
biochemical parameters), 3) determine whether the identified patterns ‘naturally’ cluster according 
to known biological sources or conditions (i.e. diagnostic T2D parameters, lipidic profile, liver, 
kidney, iron, coagulation biomarkers, or blood-related factors), 4) deeply study the fluctuation of 
clinical variables over age, by sex and by groups (Ctrl/PreDiab/Diab), and 5) estimate an aging 
clock based on the clinical variables and N-glycans and apply it to assess whether the groups of 
prediabetic and diabetic patients show an accelerated aging as compared with control, and, within 
each group, whether there are differences between the two sexes. The analytical methods employed 
were two-way partial least squares (O2PLS) and regression. Results indicate that 1) the phenomics 
and glycomics joint components are different among groups, 2) males and females follow a 
different pattern dynamics over age reflected by the relative changes of clinical variables and N-
glycans, 3) intra- and inter-correlations between joint PCs obtained integrating the phenomics data 
set or sets of endophenotypes with the glycomics data set point to a common N-glycan signature 
(instead of endophenotype-specific), and 4) a model based on the Klemera-Doubal method (KDM) 
estimates that T2DM patients are biologically older than prediabetics and controls, being this effect 
more evident for male patients. Our main conclusions are that i) a combination of N-glycans could 
be used as complementary tool for the early diagnosis of metabolic dysregulation and/or T2D, as N-
glycan changes are already present in prediabetics, ii) glycan peaks (GP) 1, GP2, and GP6 are 
confirmed as markers of aging, while GP8 and GP10 appear associated with dyslipidemia, and iii) 
this is the first time that prediabetics and diabetics have been included in an aging clock, as pure 
“healthy” controls do not exist: “the effects of atherosclerosis are superimposed on normal aging of 






1. TYPE 2 DIABETES 
1. Overview  
Type 2 Diabetes (T2D) is characterized by dysregulation of carbohydrate, lipid and protein 
metabolism. Although it is primarily caused by insulin resistance, followed by impaired insulin 
secretion, T2D is a multifactorial disease involving genetic and environmental factors (DeFronzo et 
al., 2015). 
2. Epidemiology 
The epidemic of diabetes mellitus and its complications has already become a global challenge. The 
International Diabetes Federation (IDF) estimated that 1 in 11 adults aged 20-79 years (415 million 
adults had diabetes mellitus (including type 1 diabetes (T1D), T2D, gestational diabetes) in 2015. 
This alarming numbers are calculated to raise to 642 million by 2040, and the largest increments 
will come from emerging countries transitioning from low-income to middle-income wealth (IDF 
Diabetes Atlas, 7th Edition). However, these estimates may be, in absolute numbers, 
underestimated by the current pandemic of coronavirus, which is causing many deaths in this group 
of individuals, as glycaemic control, body mass index (BMI), T2D and cardiovascular disease are 
risk factors for COVID-19 mortality (Holman et al., 2020), and by other undergoing rapid 
demographic transitions (Zimmet, 2017). The grounds for this ascending epidemic of diabetes 
mellitus are numerous and diverse: population ageing, economic development, urbanization, 
unhealthy eating habits and sedentary lifestyles (Zheng et al., 2018). Even though the genetic 
background might partially determine an individual’s response to environmental stimuli 
(Fuchsberger et al., 2016), the main drivers are the raise in obesity, a sedentary lifestyle, energy-
dense diets, and population ageing (Chatterjee et al., 2017). In fact, strong evidence points to that 
many cases of T2D could be prevented by keeping a healthy weight, engaging in a healthy diet, 
exercising daily for 30 min, avoiding smoking and consuming alcohol in moderation (Schellenberg 
et al., 2013; Hu et al., 2001).  
3. Genetics 
T2D runs in families and is heritable. The relative risk (RR) for T2D with 0 affected siblings is ~2-3 
compared with siblings of non-T2D families, but, when 2 siblings are affected, the relative risk of 
other siblings for T2D is 30. Interestingly, the RR for T2D is higher when the mother is affected as 
compared to when the father is affected. Also, RR for T2D is increased if BMI ≥30 or fasting 
glucose concentrations >5.5 mmol/L (DeFronzo et al., 2015). 
Over the last decade, plenty of genome-wide association studies (GWAS) were performed to 
identify common variants involved in T2D. In particular, in 2007 the Wellcome Trust Case Control 
Consortium (WTCCC) made a significant breakthrough by reporting single nucleotide 
polymorphisms (SNPs) associated with T2D (WTCCC, 2007). The strongest signal mapped in the 
gene TCF7L2, that up until now remains the most important SNP associated with T2D (Garagnani 
et al., 2013). Other genes significantly associated with T2D are CAPN10 (Horikawa et al., 2000), 
KCNQ1 (Yasuda et al., 2008), KCNJ11 (Gloyn et al., 2003), ABCC8 (Gloyn et al., 2003), SLC30A8 
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(Sladek et al., 2007), IDE–KIF11–HHEX (Sladek et al., 2007) and EXT2–ALX4 (Sladek et al., 
2007). However, the fact that most of the genetic variants map into (unknown) non-coding regions 
of the genome, the problem of the missing heritability (whereby the genetic loci described explain 
only a small proportion of the observed heritability, possibly due to disease heterogeneity, exclusion 
of rare variants, gene-environment interactions, gene-gene interactions and epigenetics), modest 
effect sizes, and the lack of replication of many genetic variants, inter alia, hamper the 
comprehension of the specific role each variant may have in increasing the risk for T2D. Moreover, 
novel mutations cannot explain the diabetes epidemic, which is instead largely explained by the 
epidemic of obesity. Beyond that, the majority of non-diabetic people carry risk variants for T2D, 
which roughly account for ~15% of heritability (DeFronzo et al., 2015). 
4. Diagnosis  
The diagnosis of T2D can be made on the basis of one of the following (American Diabetes 
Association, 2020): 
- Increased casual plasma glucose test (≥200 mg/dL) in patients with classic symptoms of 
hyperglycaemia or hyperglycemic crisis 
- Fasting plasma glucose levels (≥126 mg/dL) 
- 2h postload glucose level (≥200 mg/dL after 75g oral glucose)  
- Hb1Ac (≥6.5%), confirmed by repeat testing 
With regard to prediabetes, the diagnosis is established by one of the following criteria (American 
Diabetes Association, 2020): 
- Fasting plasma glucose levels (100-125 mg/dL) 
- 2h plasma glucose during 75g oral glucose tolerance test (140-199 mg/dL) 
- Hb1Ac (5.7-6.4%) 
5. Motivation 
T2D is a multifactorial complex and heterogeneous disease – the clinical presentation, underlying 
pathophysiology and disease progression in patients with diabetes can vary remarkably among 
individuals and, at times, atypical manifestation of symptoms can make clear-cut classification of 
prediabetes and diabetes difficult –. In addition, diabetes often overlaps with other complex 
pathologies, such as obesity or cardiovascular disease, and/or it may evolve to vascular 
complications. In this doctorate studies, in order to investigate the complexity of the disease, I made 
use of a rich database comprising up to 55 variables, that could be grouped in clinical and 
anthropometrical measurements, biochemical parameters (diagnostic parameters of T2D, lipid 
profile, liver profile, kidney profile, cell counts and blood differential) and N-glycans. Besides, we 
aimed to take into account the heterogeneity of all individuals, not only prediabetics and diabetics, 
but also controls, since above a certain age (~60 years) the definition of healthy controls blurs with 
preclinical age-related diseases. To achieve that, we grouped patients by sex and age ranges.  
Accordingly, the following subsections of the general introduction tackle the contextualization of 
the variables that are used in this research. 
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2. ATHEROGENIC DYSLIPIDEMIA 
6. Lipoproteins (LDL, VLDL, HDL), Cholesterol, Triglycerides and 
Apolipoproteins 
The insolubility of cholesterol and triglycerides (TG) in plasma requires that they are transported in 
macromolecules named lipoproteins, which are composed of a hydrophobic core containing 
phospholipid, fat-soluble antioxidants and vitamins, and cholesteryl ester, and a hydrophilic coat 
that contains free cholesterol, phospholipid and apolipoprotein molecules (reviewed from Hegele, 
2009). Lipoproteins can be grouped according to their densities: chylomicrons (CM), very low 
density lipoprotein (VLDL), low density lipoprotein (LDL), intermediate density lipoprotein (IDL), 
and high density lipoprotein (HDL). CM and VLDL are the main TG-carrying lipoproteins, while 
the main cholesterol-carrying lipoproteins are LDL and HDL (reviewed from Hegele, 2009).  
The terms “cholesterol”, “LDL”, and “LDL cholesterol (LDL-C)” are often used interchangeably, 
but they have different meanings. LDL refers to the particles circulating in fasting blood. Instead, 
the LDL-C term is used in clinical practice as a measure of the total amount of cholesterol 
contained in LDL particles, since plasma LDL level is generally not measured directly. Cholesterol 
is an essential component of cell membranes and a precursor of bile acids and steroid hormones; it 
can be of exogeneous and endogenous origin and it is transported to peripheral cells, mostly by Apo 
B – containing lipoproteins in plasma (reviewed from Ference et al., 2017). Analogous to LDL-C, 
HDL-C is the measure of the total amount of cholesterol contained in HDL particles.  
Patients with T2D often have lipid profiles that seem more benign than those of other high-risk 
individuals without T2D. Generally, LDL-C levels in diabetic individuals are not higher than in 
non-diabetic individuals who are matched for age, sex, and body weight. Indeed, the most frequent 
LDL-C level is “borderline high” (130-159 mg/dL) (The Expert Panel, 2002). Besides, high LDL-C 
levels (>160 mg/dL) are not found at higher rates in T2D individuals. Nevertheless, LDL-C has an 
important role in cardiovascular disease (CVD) in both T2D and non-T2D individuals. In fact, 
LDL-C levels may underestimate CVD risk in T2D (Buse et al., 2007). This is due to the LDL 
fraction characteristic in T2D individuals: small, dense particles with less cholesterol than normal-
sized LDL particles, which are exceptionally atherogenic (Krentz, 2003; Marcovina and Packard, 
2006; Goldberg, 2001). Such atherogenic nature of LDL particles in T2D individuals accounts for 
that the small, dense LDL particles are more handily oxidized and glycated and can more easily 
penetrate the arterial wall than larger LDL particles. As a result, atherosclerosis is enhanced and 
atherosclerotic plaques can increase migration and apoptosis of vascular smooth muscle cells 
(reviewed from Nesto, 2008). Accordingly, individuals with T2D have a two- to threefold increased 
risk for CVD (myocardial infarction, stroke, peripheral vascular disease) compared with non-
diabetics, and CVD is responsible for ∼80% of mortality in T2D patients (Morrish et al., 2001).   
LDL-C not only presents a major role in T2D, but it also interacts with risk factors of the metabolic 
syndrome that multiply the risk of CVD. As an example, increased small, dense LDL particles and 
raised triglycerides seem to be tied to insulin sensitivity. Insulin resistance in skeletal muscle fosters 
hepatic TG synthesis, which in the long-run generates a large amount of atherogenic TG-rich 
lipoprotein particles, specially VLDL. In turn, many TG molecules from VLDL are exchanged for 
cholesterol in LDL particles, which leads to the formation of TG-enriched (and cholesterol-
depleted) LDL. These LDL particles will become smaller and denser through the TG hydrolysis 
mediated by the hepatic lipase. Hence, adverse changes in LDL particles are positively correlated 
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with TG levels. Once TG levels exceed 100 mg/dL, small, dense LDL particles predominate 
(reviewed from Nesto, 2008). Figure 1 shows that when plasma concentrations of VLDL are high, 
cholesteryl ester transfer protein (CETP) will exchange VLDL triglyceride (TF) for cholesteryl ester 
(CE) in the core of LDL and HDL particles. This triglyceride can then be converted to free fatty 
acids by the actions of plasma lipases, primarily hepatic lipase. The net effect is a decrease in 
density of both LDL and HDL particles (Goldberg, 2001). 
 
Figure 1. Plasma lipid exchange. 
In this line, the Adult Treatment Panel III (ATP) report of the National Cholesterol Education 
Program considers elevated LDL-C as the primary target of lipid-lowering therapy for reducing 
CVD risk (NCEP, 2001). Conversely, some a posteriori studies claim that apo B and apoA1 may, 
indeed, be more powerful lipid-related predictors of risk for CVD (Packard, 2003; Sniderman et al., 
2003; Walldius and Jungner, 2004). 
Apo B-100 is a master protein component of the pro-atherogenic VLDL, IDL and LDL particles, 
each containing one Apo B molecule. Thus, plasma Apo B levels reflect the total numbers of the 
pro-atherogenic particles. TG endogenously synthesized in the liver are transported with VLDL 
particles into plasma, where they undergo lipolysis to IDL by the action of lipoprotein lipase. IDL, 
in turn, is lipolyzed by hepatic lipase, giving rise to LDL, or taken up by the liver via the LDL 
receptor. Apo B is also fundamental for the binding of LDL particles to the LDL receptor for 
cellular uptake and removal of LDL particles. In contrast, Apo A1 is the main apolipoprotein 
component of the anti-atherogenic HDL, and thus Apo A1 concentrations are strongly associated 
with HDL-C levels. Apo A1 is essentially involved in removing excess cholesterol from tissues and 
embedding it into HDL for reverse transport through the macrophage ATP-binding cassette 
transporter ABCA1 (reviewed from Chan and Watts, 2006). Chan and Watts (2006) compared 
different observational studies that used either LDL-C and/or apolipoproteins as predictors of 
coronary/cardiovascular risk. Among them, Apolipoprotein-related Mortality Risk Study (AMORIS, 
N=98,722 men and N=76,831), Second Northwick Park Heart Study (NPHSII, N=2,505 men), and 
Women’s Health Study (WHS, N=15,632 women) estimated the association of both predictors 
(LDL-C and the apolipoproteins B and A1) with CVD, and the three of them showed that the odds 
ratio (OR) of the Apo B / Apo A1 ratio is noticeably higher than the OR of LDL-C (Walldius et al., 
2001; Talmud et al., 2002; Ridker et al., 2005; Chan and Watts, 2006). 
On the other hand, HDL enhances reverse cholesterol transport and it is an immunomodulator. 
According to different studies, HDL reduces LDL oxidation (Norata et al., 2006), inhibits oxidized 
LDL-induced MCP-1 (monocyte chemoattractant protein 1) production and monocyte 
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transmigration in a co-culture of human aortic endothelial cells and human aortic smooth muscle 
cells (Van Lenten et al. 1995; Navab et al., 1991), blunts inflammatory response of endothelial cells 
to tumour necrosis factor-1 (TNF-α) and interleukin (IL)-1 stimuli (Ashby et al., 1998), and exerts 
anti-thrombotic and anti-apoptotic effects (Vergès, 2015; Femlak et al., 2017). 
HDL is composed of proteins that become affected by oxidative stress during an inflammatory 
response, including Apo A1. Modification of the protein content can turn HDL a proinflammatory 
particle, a scenario in which HDL becomes “dysfunctional”. Epidemiological research has shown 
that HDL levels are inversely correlated with the risk of CVD. However, there are individuals who 
have suffered a clinical event and present normal or high levels of HDL. Low levels of HDL 
cholesterol are also associated with increased risk for type 2 diabetes. The hypothesis of 
“dysfunctional” HDL has been studied in T1D. Overall, T1D patients with lowered levels of HDL-
C have a higher cardiovascular risk, but T1D patients with high levels of HDL-C may not have a 
lower cardiovascular risk (Orchard, 1990). Thus, the mechanisms of such relationship are yet to be 
understood. To date, though, it has been suggested that different HDL subfractions relate to 
coronary artery disease (CAD) incidence in a different manner (reviewed from Femlak et al., 2017).  
1. BMI and WHR 
Along with the lipid profile, some anthropometric measures are also taken into account as a 
function of health in patients. A few well-known parameters are waist circumference (WC), waist-
to-hip ratio (WHR), and BMI. There has been controversy in whether BMI or WHR is a better 
predictor of obesity (Murray, 2006; Qyao and Nyamdorj, 2010). Qyao and Nyamdorj (2010) revised 
different investigations with the goal of comparing between BMI, WC, and WHR in their relation to 
the incidence and prevalence of T2D. They concluded that all studies showed that either BMI or 
WC predicted or was associated with T2D independently and stressed that the nature of the study 
could condition on results. In other words, prospective studies favoured equally BMI, WC, WHR 
and the waist-to-stature ratio (though these studies were limited to ethnic groups), while cross-
sectional studies evidence pointed to that WC or WHR discriminate better cases with diabetes from 
those without, as compared with BMI (though these studies provide only possible association). 
Another investigation aimed to explore both the relative magnitude of association and the 
discriminative capability of multiple indicators of obesity with CVD mortality risk by conducting a 
meta-analysis of 9 cohort studies of men and women from the British general population 
(Czernichow et al., 2014). They measured BMI, WC, and WHR, and, after a mean of 8.1 years of 
follow-up, 6,641 deaths were recorded from a total of 82,864 individuals. In this research, they 
estimated the association of CVD risk and CVD mortality with the mentioned variables and reached 
the conclusion that measures of abdominal adiposity, but not BMI, were related to an increased risk 
of CVD mortality (Czernichow et al., 2014). In any case, the increasing adiposity is the single most 
important risk factor for T2D (De Fronzo et al., 2015). Figure 2, extracted from De Fronzo et al. 
(2015), shows the relationship between the age-adjusted RR of T2D and BMI and reflects that the 




Figure 2. Association between BMI and T2D 
7. Common risk factors in cardiovascular disease and type 2 diabetes 
Thus far, I reviewed the role of key players in CVD and T2D without clearly distinguishing 
between the two diseases, which, indeed, share many traditional and non-traditional risk factors. 
Traditional CVD risk factors in T2D include dyslipidemia (altered lipid profile), increased blood 
pressure, being overweight or obese (>25 kg/m2), having abdominal or central obesity (independent 
of BMI), reduced physical exercise, and cigarette smoking. Non-traditional CVD risk factors 
comprise insulin resistance and hyperinsulinemia, postprandial hyperglycaemia, glucose variability, 
microalbuminuria, haematological factors, thrombogenic factors, increased levels of C-reactive 
protein (CRP), homocysteine and vitamins, erectile dysfunction, and genetics and epigenetics. 
There are consistent evidences which underscore that control of the traditional risk factors are 
necessary for reducing CVD risk in T2D patients. Cardiovascular benefits are acquired if the 
control of such risk factors start early in subjects with short duration of diabetes and low 
cardiovascular risk. On the contrary, in elderly subjects with a longer time exposure to 
hyperglycaemia and high cardiovascular risk, there are no cardiovascular improvements but losses. 
This positive or negative effect could be attributed to the “metabolic memory” hypothesis, whereby 
the early glycaemic exposure is imprinted in target organs, resulting in long-term protective or 
deleterious consequences (reviewed from Martín-Timón et al., 2014). The main gain of reducing 
concentration of plasma glucose in T2D is prevention of long-lasting microvascular complications 
and, to lesser extent, of macrovascular complications. However, hyperglycaemia is a loose risk 
factor for CVD (UKPDS, 1998; Holman et al., 2008), and interventions (Gerstein et al., 2008; Patel 
et al., 2008; Duckworth et al., 2009) focusing on reducing plasma glucose have unsuccessfully 
reduced CV risk and mortality. The cluster of CV/metabolic factors (obesity, dyslipidemia, 
hypertension, endothelial dysfunction, procoagulant state) associated with insulin resistance, that is 
usually moderate to severe in individuals with T2D, is known as insulin resistance (metabolic) 
syndrome and is a combinatorial major factor responsible for CV risk in T2D (DeFronzo, 2009; 
DeFronzo, 2010; Abdul-Ghani et al., 2017). In this line, obese non-T2D individuals but with insulin 
resistance syndrome exhibit an akin raised risk for CVD compared with T2D individuals, which 
reinforces the notion that hyperglycaemia is not a paramount risk factor for CVD. In accordance 
with this, antidiabetic drugs (e.g. insulin, sulfonylureas, and dipeptidyl peptidase 4 (DPP-4) 
inhibitors), which diminish plasma glucose without affecting insulin resistance, do not lessen CVD 
risk and mortality in T2D (Abdul-Ghani et al., 2017). 
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2. Prediabetes is Key for Understanding Cardiovascular Complications in Type 2 
Diabetes 
Prediabetes is characterized by one of the following (DeFronzo et al., 2015):  
➢ Impaired fasting glucose (IFG): muscle insulin resistance + impaired late insulin secretion. 
➢ Impaired glucose tolerance (IGT): hepatic insulin resistance + impaired early insulin 
secretion. 
➢ ↑Glycated haemoglobin (HbA1c). 
Both IFG and IGT use hyperinsulinemia as a coping mechanism to reduce elevated fasting or 
postprandial glucose (Laakso, 2010). Some studies, though, have provided evidence that individuals 
with IGT have a more marked degree of insulin resistance, whereas individuals with IFG are 
characterized by a more marked β-cell defect (Weyer et al., 1999; Festa et al., 2004). In addition to 
that, it has been shown that insulin resistance per se is correlated with atherosclerosis, even in 
normoglycemic individuals (Laakso et al., 1991). Furthermore, several investigations have 
demonstrated that high insulin level is associated with risk of cardiovascular heart disease (CHD) 
(Laakso, 1996). Prediabetics have a cluster of CVD risk factors that may differ of the cluster of 
CVD risk factors in diabetics. Nevertheless, diabetics are at least as insulin resistant as prediabetics 
(Laakso, 1996). Therefore, insulin-resistance RR in both prediabetics and diabetics are likely to 
explain an important part of the atherosclerotic process (figure 3, extracted from Laakso, 2010).  
 
Figure 3. Relative risk of CVD in normoglycemia, prediabetes and diabetes 
3. Sex in Cardiovascular Complications in Type 2 Diabetes 
Intriguingly, RR for CHD is higher in T2D female patients than in T2D male patients. The reason 
for this sex difference is not known, but it could be explained by a heavier risk-factor burden and a 
greater effect of blood pressure and atherogenic dyslipidemia on the risk of CVD in T2D women 
than in T2D men (Juutilainen et al., 2004).  
8. Thrombosis and fibrinolysis 
Insulin resistance and diabetes are associated with an increased prothrombotic risk (coagulation 
factors VII, XII, and fibrinogen) and with suppressed fibrinolysis, due to elevated levels of the 
fibrinolytic inhibitor PAI-1 and of the thrombin-activatable fibrinolysis inhibitor (TAFI) (Grant, 





9. Glycans definition  
The terms glycan and polysaccharide are defined by IUPAC as synonyms meaning "compounds 
consisting of a large number of monosaccharides linked glycosidically". In practice, glycan, 
carbohydrate, saccharide and sugar are generic terms used interchangeably (IUPAC Gold Book – 
Glycans). Figure 4 shows some examples of glycans. 
 
Figure 4. Examples of glycans (IUPAC Gold Book) 
Glycans are not only defined by monosaccharide units, but also by the bond position, its anomeric 
configuration (alpha or beta), the number of branches and the position of branching (Lauc and 
Zoldoš, 2010). Along with nucleic acids, proteins and lipids, glycans are essential macromolecular 
and structural components or, in other words, building blocks, of all cells, and they can be found 
attached to proteins and lipids or as independent macromolecules (Marth and Grewal, 2008). 
10. Glycans biosynthesis 
In the case of protein glycosylation, glycans synthesis can be split into N-linked, O-linked, and the 
GlcNAc modification (revised from Zhou et al., 2018): 
▪ N-glycosylation synthesis: N-linked glycosylation starts with the transfer of a large 
precursor oligosaccharide from a membrane-embedded dolichol phosphate lipid to the 
asparagine of a nascent protein while being synthesized in the rough endoplasmic reticulum 
(ER). The glycan assists in protein folding by mediating interactions with ER chaperones 
like calnexin and calreticulin, thereby functioning as a quality control checkpoint. Upon 
proper folding, the glycans are trimmed to “high mannose” structures prior to moving to the 
Golgi apparatus, where they undergo further trimming and then rebuilding through the 
combined action of various glycosyltransferases. This results in both hybrid and complex- 
type N-glycans, which are common at the plasma membrane and on secreted glycoproteins, 
including immunoglobulin (Ig) G and essentially every surface protein on a cell (reviewed 




Figure 5. Protein N-glycosylation biosynthesis 
▪ O-glycosylation synthesis: O-linked glycosylation is a wide category comprising various 
modifications named for the glycosidic linkage of oxygen on threonine or serine residues, 
and includes O-GalNAc, O-fucose, and O-mannose glycans. Unlike the co-translational N-
glycosylation, all of these are built progressively from a single initiating sugar post-
translationally cell (reviewed from Zhou et al., 2018). 
▪ O-GlcNAcylation (O-GlcNAc glycosylation): O-GlcNAc glycosylation corresponds to the 
addition of N-acetylglucosamine on serine and threonine residues of cytosolic and nuclear 
proteins. O-GlcNAcylation is a dynamic post-translational modification, analogous to 
phosphorylation, that regulates the stability, the activity or the subcellular localisation of 
target proteins (e.g. RNA polymerase II, histones, histone deacetylase complexes and 
members of the Polycomb and Trithorax group). This reversible modification depends on 
the availability of glucose – 2-5% of glucose enters the hexosamine biosynthetic pathway 
(HBP) – and therefore constitutes a powerful mechanism by which cellular activities are 
regulated according to the nutritional environment of the cell (as above-mentioned GlcNAc 
is considered to be the metabolic sensor of the cell). O-GlcNAcylation has been implicated 
in important human pathologies including Alzheimer disease and type-2 diabetes. Only two 
enzymes, OGT and O-GlcNAcase, control the O-GlcNAc level on proteins (reviewed from 




Figure 6. O-GlcNAcylation in cell metabolism 
11. Molecular diversity of glycans 
Glycosylation is not only the most abundant post-translational modification, but also by far the most 
structurally diverse. Conservative estimates state that >50% of proteins are glycoproteins, without 
considering the countless number of nuclear and cytoplasmic proteins modified by O-GlcNAc. It is 
estimated that between 2-5 glycans are attached to an average glycoprotein, the 10% of which are 
O-linked, and the other 90% are N-linked or both (Apweiler et al., 1999). In this line, there are at 
least 13 different monosaccharides and 8 different amino acids involved in glycoprotein linkages, 
with a total of at least 41 different chemical bonds known to be linking the glycan to the protein 
(Spiro, 2002). Importantly, each one of these glycan:protein linkages is unique in both structure and 
function. However, if the structural diversity of different branches composed by different 
monosaccharides is added to these single-linkages, the molecular diversity increases exponentially. 
Just the “sialome” rivals or exceeds many other post-translational modifications in abundance and 
structural/functional diversity. Besides, chemical modifications, such as phosphorylation, sulfation 
and acetylation, increase the glycan structural/functional diversity even more. Therefore, 
categorizing glycosylation as a single type of post-translational modification may be misleading and 
useless (Cohen and Varki, 2010). 
12. Functions of glycans 
Very conservative estimates indicate that there are over a million different glycan structures in a 
mammalian cell's glycome, and consequently glycoproteins are involved in a myriad of functions. 
Varki (2017) revised the multiple functions of glycans, and classified them into four groups (see 
figure extracted from Varki, 2017):  
i. Structural and modulatory roles: as example, the addition of O-GlcNAc residues to 
histones surrounding chromosomal DNA is key in the histone code that regulates gene 
expression. 
ii. Extrinsic (interspecies) recognition of glycans: as example, glycans, such as 
polysaccharide A, derived from the mammalian gut microbiome, helps to modulate the host 
immune system to a more tolerant state (via T-reg engagement). 
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iii. Intrinsic (intraspecies) recognition of glycans: as example, the conservative 
glucosylation/deglucosylation cycle of protein folding in the ER. 
iv. Molecular mimicry of host glycans: as example, molecular evolution of microorganisms 
has allowed them the acquisition of host sialoglycans or the direct transfer of host sialic 
acids by trans-sialialidases, thereby acting as self-associated molecular patterns (SAMPs) 
recognized by Siglecs – receptors of sialoglycans –, limiting complement activation, or 
masking antibody recognition. 
 
Figure 7. Biological roles of glycans proposed by Varki (2017) 
13. Genetics of protein glycosylation 
The synthesis of glycans, in contrast to genes, is a template-independent process – glycans are 
encoded in a dynamic network of hundreds of genes that code for enzymes involved in glycan 
synthesis, e.g. glycosyltransferases (>250), glycosidases, enzymes for sugar nucleotide 
biosynthesis, etc. In addition to over 600 such proteins, there are various transcription factors, Golgi 
organizers, proton pumps, etc. that affect their expression and activity (reviewed from Lauc and 
Zoldoš, 2010). 
In genetics, three groups of mutations/SNPs in genes coding for enzymes involved in glycosylation 
have been described at large:  
a. Embryologically lethal: those affecting enzymes involved in the pathway of glycans 
biosynthesis, and that consequently they impair the proper functioning of thousands of 
proteins (reviewed from Lauc and Zoldoš, 2010). 
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b. Rare mutations: those comprising a group of rare genetic disorders (the so-called 
congenital disorders of glycosylation or CDC) caused by mutations in the core N-
glycosylation pathway – these mutations result in residual enzymatic activity, but are 
nonetheless associated with significant mortality and broad motoric, immunologic, 
digestive and neurologic symptoms (reviewed from Lauc and Zoldoš, 2010). 
c. Glycophenotype: those variations in genes involved in modifications of glycan antennas, 
which are common in the population and apparently cause a large part of individual 
phenotypic variations that exist in humans and in other higher organisms. Indeed, the 
majority of variability originates from SNPs that individually do not have visible 
glycophenotypes, but if present in specific combinations within the same individual can 
have significant phenotypic effects (reviewed from Lauc and Zoldoš, 2010). 
Regardless of mutations/SNPs, it has been reported that a large part of the observed variability is 
under genetic control (Lauc and Zoldoš, 2010). 
14. Environmental factors affecting protein glycosylation 
The complex dynamic network of hundreds of proteins taking part in glycans biosynthesis makes 
the process of protein glycosylation intrinsically sensitive to all changes occurring within a cell, so 
that the glycan structures produced at any instant of time reflect the significant past events in the 
cell. Indeed, glycosylation sites on the same protein can contain different glycan structures that 
reflect the cell type, developmental stage and metabolic state of the cell in which they are 
synthesized. 
While general glycan structures appear to be mostly defined by the genetic makeup, some specific 
glycans are sensitive to environmental factors. Some examples of environmental factors that change 
















MATERIALS & METHODS 
15. Data description 
4. Clinical database 
A database consisted of 123 variables (including 10 N-glycans) of N=1185 individuals was 
provided. The clinical data were classified in groups to facilitate the comprehension (table 1). 
Table 1. Database classified variables by biomedical groups 
GROUP VARIABLE 







Chronic Renal Insufficiency 
Retinopathy 
Arteriopathy Obliterans of Lower Limbs 
Arteriopathy Obliterans of Upper Limbs 
Cardiac Ischemia 

























Estimated glomerular filtration rate 
C Reactive Protein 
Fibrinogen 
PAI-1  
Thrombin activatable fibrinolysis inhibitor 










Symmetric Dimethylarginine  
Asymmetric Dimethylarginine  
ASAH1 (lysosomal enzyme) 
ASAH1 (lysosomal enzyme percentage) 
Glucoamylase (lysosomal enzyme) 








Mean Corpuscular Volume 
Mean Corpuscular Hemoglobin 
Mean Corpuscular Hemoglobin Concentration 
Red blood cell Distribution Volume – SD 
Red blood cell Distribution Width – CV 
Platelets 
Platelets Distribution Width – SD 
Mean Platelets Volume 
Blood Differential 






































Metabolic Syndrome (ATPIII diagnosis)* 









Hypertension Onset Year 
Cholesterol Medication 
Hypercholesterolemia Onset Year 
Acute Myocardial Infarction 
Acute Myocardial Infarction Onset Year 
Ictus 















*ATPIII: adult treatment panel III; *IDF: international diabetes foundation; unk: unknown; yellow ochre 
color: variables used in all analyses; green color: variables used for the global O2PLS; grey color: 
variables never used. 
 
The variables in gray (a total of 32) were removed – except the “Diabetes” variable –, either 
because they were redundant with other variables or were out of the scope of this research.  
5. N-Glycans 
10 quantified total plasma N-glycan abundances measured with DSA-FACE were used for the 
analysis (table 2).   





































16. Preprocessing: Clinical Database and N-glycans 
Summary of the preprocessing – Phenomics data set 
The preprocessing was run 3 times for the exploratory data analysis (EDA) visualization plots. On 
the 1st time 2 impossible values were detected: Height=110cm (BMI=61), Glucoamylase_Lys.Enz=-
80.3 (negative value), which were considered as missing values. Plots and summary tables were 
obtained and a screening was made for extreme outliers (>3/4 times the 0.01/0.99 percentiles), and 
13 values were removed. After that, preprocessing was run a second time, in which variables that 
were skewed were transformed and pairs of variables considered redundant (highly correlated) were 
filtered (1 out of the pair). The 3rd run contains plots from the whole processed data set. 
6. Categorical variables to binary 
The variables “Anti-aggregants”, “Vasodilators”, “Anti-arrythmics”, “Anti-inflammatories” and 
“Statins” from the group “Medication” were all converted to binary, i.e. she takes medication – 
YES/NO, instead of considering the class of drug. 
7. Center log-ratio (clr) transformation on N-glycans and Blood cells % 
Compositional data are measures of proportions, percentages, parts per million, etc. which sum up 
to the unity or 100 constraint. In the case of N-glycans, this means that when they are transformed 
to percentage, the level of one glycan increases at the expense of the decrease of (another) 
glycan(s). This might lead to a misinterpretation of the correlation coefficients between the original 
glycans, commonly referred as the negative bias problem (Houwing-Duistermaat et al., 2017). To 




clr(x) = (log(x1/g(x)), …, log(xD/g(x))) 
where x represents the composition vector, g(x) is the geometric mean of the composition x, and xD 
is Euclidean distances between the individual N-glycan variables. The clr was carried out with the 
compositions package from R software. In figure 8 the glycans distribution is shown for non-clr and 
clr transformed glycans. 
Before applying clr transformation, it was noted that 17 rows in the Glycomics data set were 
completely missing, and thus removed (N=1168). No other missing values were detected in the data 
set. 
 
Figure 8. Distribution of N-glycans without vs without clr transformation 
The same applies to blood cell percentages, thereby the sum of neutrophils %, lymphocytes %, 
basophils %, eosinophils % and monocytes % equals 100. Accordingly, the clr too was performed 
in blood cell counts (figure 9). These 5 variables had a total of 6 NA, but it should be noted that the 
clr deals with missing values when performing the transformation. 
The clr on N-glycans and blood cells was conducted on separate dataframes (df), respectively; 




Figure 9. Distribution of Blood Cells without vs without clr transformation 
8. Missing values and imputation 
1164/1168 rows contained missing values, which were present in 70/122 columns. Briefly, 96 
variables had <1% NA, 11 variables had 1-25% NA, 0 variables had between 25-50% NA, and 16 
variables >50% NA. 
The 16 variables >50% NA were deleted, so that the final number of clinical variables became 106. 
All 106 (≤25% NA) were imputed with the mice package. 
9. Outliers detection and treatment 
After a first process of data cleaning (following NA deletion or imputation), different plots 
(histograms, Q-Q plots, boxplots) and tables (summary statistics and quantiles) were produced (data 
not shown). Cohorts are explained in the next section, but so far N=292 controls (Ctrl), N=313 
prediabetics (PreDiab) and N=563 diabetics (Diab). 
These EDA served to check for data distribution and to detect whether there could be possible 
influential outliers that could drastically bias/change the fit of estimates and predictions. 
In general, values were not extreme, indicating that the best is to include them over other methods, 
like trimming based on reference values – up to 130 samples would be lost – or winsorizing, i.e. 
imputing the most external top and bottom outliers to the 5th and the 95th quantiles, which would 
introduce bias. Based on the EDA, the following extreme outliers were detected: 
• Age: 17-Ctrl 
• Creatinine: 6-Ctrl 
• HOMA: 47.3-Diab 
• Triglycerides: 1528-Diab 
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• Estimated glomerular filtration rate (EGFR): 364.8-PreDiab, 7.3-Ctrl 
• C Reactive Protein: 130.6-PreDiab 
• Gamma Glutamyl Transpeptidase: 946-Diab 
• Total Bilirubin: 7.5-Diab, 9-Ctrl 
• Ferritin: 1500-PreDiab 
• Platelets: 965-Diab 
• Alkaline Phosphatase: 300-Ctrl, 410-Diab 
These values were removed (except for a technical reason the “EGFR=7.3-Ctrl” (ID and value 
could not be read by R)), giving to: N=288 Ctrl, N=310 PreDiab and N=557 Diab (final N=1155). 
10. Descriptive Statistics 
After dealing with missing data and extreme outliers, data were visually check for normally 
distribution or skewness through histograms, Q-Q plots, boxplots and tables of summary statistics 
(data not shown). From plots and tables it could be inferred that the following variables are: 
• Highly right skewed: Creatinine, AST, HOMA, ALT, Triglycerides, Insulin, C Reactive 
Protein, Gamma Glutammyl Transpeptidase, Ferritin, Alkaline Phosphatase, Azotemia, 
Uric Acid, Telomere Length, Symmetric Dimethylarginine, Asymmetric 
Dimmethylarginine, Red blood cell Distribution Width. 
• Highly left skewed: Mean Corpuscular Volume. 
1. Kolmogorov-Smirnov test 
For the 17 highly right skewed variables, a Kolmogorov-Smirnov (K-S) normality test was 
performed to numerically check for normality. “Cholesterol” was used as reference variable, since it 
follows a fair Gaussian distribution. The null hypothesis that each of the skewed variables follows a 
normal distribution and, thus, it is not different from the “Cholesterol” distribution was rejected in 
all skewed variables (p-value < 2.2e-16). 
11. Skewed Continuous Variables Transformation 
Next, 10 different transformations were tested in each variable – log, square root, raise to the power 






• No transformation: Mean Corpuscular Volume. 
• Log: Creatinine, AST, ALT, Triglycerides, Insulin, Gamma Glutamyl Transpeptidase, 
Alkaline Phosphatase, Azotemia, Uric Acid, Telomere Length, Red blood cell Distribution 
Width. 
• Square root: Symmetric Dimethylarginine, Asymmetric Dimethylarginine. 
• Raise to the power 0.125: Ferritin. 
• Raise to the power 0.275: C Reactive Protein. 
• Raise to the power 0.3: HOMA. 
12. Redundant Correlated Variables Filtering 
A high correlation between two variables means they have similar trends and are likely to bring 
similar information. This can bring down the performance of some models drastically (e.g. linear 
and logistic regression models (Sharma P (2018)).  
A Pearson correlation matrix between numerical variables was calculated, and for variables 
crossing a certain threshold, one of them was deleted. Since dropping a variable is highly 
subjective, choosing between one of them was done based on domain knowledge, so that, for 
example, for blood variables, those already surpassing a threshold of ≥ 0.5 or ≤ -0.5 were removed, 
while for the rest of variables a threshold of ≥ 0.7 or ≤ -0.7 was set, excluding core variables for the 
study, such as HbA1c/HOMA. Ten variables (7 blood-related and 3 lysosomal enzymes) were 
dropped: 
• Basophils 
• Red blood cell Distribution Volume – SD 
• Mean Corpuscular Hemoglobin Concentration 
• Hematocrit 
• Platelet Large Cell Ratio 
• Platelets Distribution Width – SD 
• Mean Corpuscular Hemoglobin 
• Glucoamylase 




A second Pearson correlation matrix was computed after filtering for those variables, to visually 
assess for correlations among the remaining variables (not shown). 
17. Cohorts: controls, prediabetics, diabetics 
As mentioned before, N=288 Ctrl, N=310 PreDiab and N=557 Diab (final N=1155). 
These cohorts were established by the diabetologists of Ancona (where the database was produced), 
who determined if individuals were diabetics or not. However, since there is a time gap between the 
diagnosis of T2DM – ranging from 70’s up to the early 2000, being the 2 most recent diagnosed 
individuals in 2005, plus incomplete cases – and the data collection – year 2009 –, it was considered 
appropriate to redefine the groups based on the 2 first diagnostic reference values from table 
(extracted from De Fronzo et al. 2015), in agreement with the American Diabetes Association 
(ADA), because they could be more informative than the previous ones. For that, I did not change 
the “diabetes” status established by the diabetologists from Ancona (to date, diabetes cannot be 
cured, just controlled), and I just took the individuals with absence of diabetes (according to the 



















CHAPTER 1: Characterization of the T2D-Dysmetabolic-Aging 
Phenotype 
4. INTRODUCTION 
Aging is a time-dependent multifactorial process that results in a global deterioration of the 
physiological functions and elevated risk of pathologies, including CVD, neurodegenerative 
diseases, cancer and diabetes (López-Otín et al., 2013). Over recent years, the new approach termed 
“Geroscience” has focused the attention on a limited number of highly interconnected “pillars”, 
shared between aging and age-related diseases (López-Otín, 2013; Kennedy et al., 2014). Among 
them, inflammation plays a key role, though being indispensable for survival and paradoxically 
non-detrimental in childhood and adulthood (Furman et al., 2019). A particular feature of the old 
immunophenotype is the chronic, low-grade, sterile inflammation status, termed inflamm-aging, 
that can be largely explained by a disequilibrium between inflammatory and anti-inflammatory 
networks. Within this context, immune cells are major players in eliciting inflammatory responses 
and constantly adapting their functions at facing internal and external stimuli, but not unique.  
Different organs, tissues and cells, such as adipose tissue (AT), liver, muscle, fibroblasts or 
endothelial cells, are also capable of inducing a proinflammatory status, thus contributing to 
systemic inflammation and to subsequent chronic diseases (Salvioli, 2013). Of note, adipocytes and 
hepatocytes are pivotal metabolic cells that, under chronic overnutrition, promote inflammatory 
local pathways, which, in turn, drive the recruitment of proinflammatory macrophages. In the long 
run, this may result in obesity, CVD and hepatic steatosis, which constitute intermediary 
phenotypes that combined raise risk for metabolic syndrome (MetS) (Grundy et al., 2004). Besides, 
chronic obesity-associated inflammation greatly contributes to insulin resistance and posterior β-cell 
inflammation and dysfunction, increasing risk for T2DM. Within this framework, a common 
denominator for these maladies is the low-grade, chronic inflammation state induced by metabolic 
cells in response to excess nutrients and energy, termed metaflammation (Gregor et al., 2011).  
Metaflammation and inflamm-aging share molecular mechanisms of inflammation that characterize 
aging and age-related diseases. For example, inflammatory cytokines can impair the insulin 
signalling pathway by inactivating the insulin receptor substrate 1 (ISR1) via phosphorylation, thus 
leading to the inactivation of the phosphatidylinositol-3-kinase (PI3K)-Akt path. From a clinical 
point of view, some T2DM patients are non-obese and some obese patients are non-diabetic, but 
anti-inflammatory drugs do not prevent diabetes and CVD events progression, which points towards 
inflammation as link between obesity and diabetes development (Franceschi et al., 2000; Franceschi 
et al., 2017; Prattichizzo et al., 2018). Though, immunometabolic disorders often come up in 
clusters and nurture aging and age-related diseases (Hotamisligil, 2006; 2017). In point of fact, the 
World Health Organization estimates that 39% adults worldwide are overweight and 13% are also 
obese, and that between 2015 and 2050 the world's population over 60 years will increase from 12% 
to 22%. These worrisome numbers challenge biomedical research at identifying new biomarkers for 
the diagnosis of age-related diseases. A field that has a lengthy trajectory, but it is only recently 
being recognized by immunologists, is glycomics (Zhou et al., 2018), upon which this chapter will 
focus on for reviewing shared links between inflamm-aging and metaflammation. 
Glycomics refers to the studies that strive for defining and quantifying the glycome of a cell, tissue 
or organism (Hart and Copeland, 2010). The glycome is the entire set of glycans, or carbohydrates, 
and glycoconjugates produced by a cell or organism under specific conditions (Bertozzi and 
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Sasisekharan, 2009). The covalent addition of glycans to proteins and lipids, termed glycosylation, 
is the most abundant post-translational modification and by far the most structurally richest. In 
mammalian cells, protein glycosylation can be mainly classified into three classes: the co-
translational N-linked glycosylation, the post-translational O-linked glycosylation, and the O-linked 
β-N-acetylglucosamine (O-GlcNAc) modification (O-GlcNAcylation). N-linked chains are those 
glycans attached to the nitrogen of asparagine; O-linked glycans are the ones attached to the oxygen 
of serine or threonine residues, and comprise O-linked N-acetylgalactosamine(O-GalNAc), O-
fucose, and O-mannose glycans; while O-GlcNAcylation is an ancient modification whereby 
GlcNAc is swiftly added or removed, being uridine diphosphate (UDP)-GlcNAc the metabolic 
sensor of cellular condition (Zhou et al., 2018). Not surprisingly, these post-translational 
modifications directly or indirectly take part in a myriad of cellular and extacellular functions 
(Varki, 2017). Importantly, glycans and glycan-binding proteins are core to a properly functioning 
immune system (Johnson et al., 2013), and the genetic makeup and environmental changes can 
significantly impact the glyco-immune homeostasis, favouring/triggering different pathological 
conditions (Lauc and Zoldoš, 2010). These encompass infectious and complex diseases, including 
cancer, neurological disorders and severe inflammation (Moran et al., 2011, Theodoratou et al., 
2014), as well as the aging process. Aberrant changes in glycosylation are particularly relevant for 
immunoglobulin G (IgG) effector functions, since these antibodies can prompt proinflammatory 
responses and fuel metaflammation and inflamm-aging. Indeed, glycoforms of the immune system 
and of circulating proteins can be captured by examining either the whole spectrum of N-linked 
glycans (N-glycome) or the N-glycans attached to IgGs (IgG glycome) present in serum or plasma. 
In this regard, recently developed high-throughput (HTP) methods have significantly enhanced 
investigations on N-glycans. 
In this chapter, we briefly introduce the main characteristics of glycosylation and the 
immunometabolic crosstalk between aging and metabolic syndrome. Then, we describe the 
pathophysiological roles of glycans and their receptors in inflamm-aging and metaflammation. 
Finally, we discuss the most relevant N-glycan biomarkers in these inflammatory processes.  
 
18. Intracellular biological roles of glycans: focus on cellular metabolism 
13. Metaflammation intra-organ 
crosstalk 
Obesity elicits various triggering events (step 1), 
such as hypoxia, lipotoxicity, ER stress, that 
initiate activation of inflammatory signaling 
pathways in parenchymal cells, such as 
adipocytes and hepatocytes (Lee et al., 2018; 
figure 10).  
These cells, in turn, secrete different chemokines, 
which drive chemotaxis and migration of 
macrophages and other immune cell types, into 
Figure 10. Metaflammation intra-organ crosstalk 
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the underlying tissue (step 2; Lee et al., 2018; figure 10). 
Overall, these immune cells take on a proinflammatory phenotype and secrete a number of factors 
(cytokines, galectin-3, exosomes; step 3), which exert local paracrine effects to cause insulin 
resistance in adipocytes, hepatocytes and myocytes, or decreased insulin secretion stimulated by 
glucose in beta cells (step 4; Lee et al., 2018; figure 10). 
14. Metaflammation inter-organ crosstalk 
Obesity gives rise to chronic inflammation in metabolic tissues (liver, adipose tissue, muscle; figure 
11, extracted from Lee et al., 2018). It also promotes dysbiosis in the gastrointestinal tract and 
gliosis in the central nervous system. These tissues secrete factors that not only act locally (as 
paracrine effects), but also enter the bloodstream to cause distal effects on insulin sensitivity and 
food intake. Each factor has the potential to foster the production and secretion of some other 
factors, adding to the complexity of the integrated network comprising metabolic inter-organ 
crosstalk (Lee et al., 2018). 
 
Figure 11. Metaflammation inter-organ crosstalk 
15. Metaflammation intracellular crosstalk 
In obesity, NF-kB can be turned on by multiple mechanisms (figure 12, extracted from Catrysse 
and van Loo, 2017): microbiota-derived lipopolysaccharide (LPS), free fatty acids (FFAs), 
advanced glycation end products 
(AGEs), inflammatory cytokines, 
oxidative stress, and ER stress all 
recruit inflammatory signaling 
cascades activating NF-kB kinase 
subunit 2 (IKK2). On activation, 
IKK2 will phosphorylate insulin 
receptor substrate (IRS) proteins on 
inhibitory Ser sites, prompting insulin 
resistance. In addition, IKK2 can 
induce the activation of the inhibitory 
insulin regulatory proteins 
mammalian target of rapamycin 
(mTOR) and ribosomal protein S6 
kinase1 (S6K1) by suppressing the 
Figure 12. Metaflammation intracellular crosstalk 
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activity of tuberous sclerosis 1/2 (TSC1/2). NF-kB also affects insulin signaling by transcriptional 
induction of protein tyrosine phosphatase 1B (PTP1B) and suppressor of cytokine signaling 3 
(SOCS3), which can both interfere with the phosphorylation state of IRS proteins. Also, ceramide 
biosynthesis genes are upregulated, leading to increased production of ceramide from FFA 
metabolism and the activation of protein kinase C (PKC), which contribute to the development of 
insulin resistance. NF-kB signaling also induces a low-grade inflammatory environment by driving 
the production of a wide range of inflammatory chemokines and cytokines, which further leads to 
the recruitment of immune cells, augmenting the inflammatory response (Catrysse and van Loo, 
2017). 
16. Glucotoxicity in the frame of metaflammation 
In this subsection, a mechanism contributing to metaflammation is described. Accordingly, the 
higher the input concentration of glucose and glutamine to the cell, the higher the concentration of 
UDP-GlcNAc, and, consequently, more proteins become O-GlcNAcylated (Issad et al., 2010; 
figure 13). 
 
Figure 13. O-GlcNAcylation in conditions of hyperglycaemia 
Insulin activates the Akt/PI3K pathway in the cell, which subsequently boosts glucose transport and 
metabolism. ~2-5% of glucose is directed towards the HBP, which induces the biosynthesis of 
UDP-GlcNAc, the OGT substrate. OGT goes to the plasma membrane and glycosylates (O-
GlcNAcylation) the proximal elements of insulin signaling, resulting in signal attenuation. In 
chronic hyperglycemia, this chronic glycosylation in signaling proteins may foster the deterioration 





Figure 14. Relationship between chronic glycaemia, chronic glycosylation and insulin sensitivity 
However, it has not been established a direct causal relationship between the increase in the UDP-
GlcNAc intracellular levels and the development of insulin resistance, since, even though that the 
raise in the intracellular concentrations of glucose and glutamine results in the increase of UDP-
GlcNAc and O-GlcNAc levels, there are three factors accounting against this idea: 1) the increase in 
oxidative and ER stress, that promotes chronic inflammation and insulin resistance; 2) UDP-
GlcNAc inhibits the glutamine-fructose-6-phosphate transaminase (GFAT) enzyme, which is the 
rate limiting enzyme controlling the HBP flux, and 3) the inhibition of OGT in animal models in 
hyperglycaemic conditions still results in insulin resistance (reviewed from Copeland et al., 2008).  
Hyperglycemia is not only linked to 
insulin resistance, but also to 
cardiovascular disease. In conditions of 
hyperglycemia (muscle/fat), there is an 
activation of glucose responsive genes that 
are associated to insulin resistance (figure 
15). For example, the transcription factor 
SP1 is glycosylated by OGT and it 
enhances the expression of PAI-1, which 
is an inhibitor of fibrinolysis, and TGF 
beta, a profibrotic factor, which contribute 
to atherosclerotic lesions in obese and 
diabetic patients. But there can be 
involved many transcription factors, genes 
and proteins (Copeland et al., 2008). 
Another important thing in CVD is that endothelial dysfunction is an abnormality that may 









17. Lipotoxicity in the frame metaflammation 
In this subsection, another 
mechanism involving protein 
and glycosylation and T2D is 
summarized. In islets from 
wild-type mice fed with 
normal chow, Foxa2 and 
HNF1a control the 
expression of Slc2a2 (Glut2) 
and of Mgat4a (GnT-4a, an 
N-acetylglucosamine 
transferase, figure 16, 
extracted from Thorens, 
2011). GnT-4a is required for 
the formation of a N-glycan 
structure on Glut2 (and Glut1 
in human islets), a process 
that takes place in the 
secretory pathway. The N-glycan is required to anchor Glut2 at the cell surface through interaction 
with a lectin, galectin9 (Gal9). In HFD-fed mice or upon exposure of mouse or human islets to 
palmitic acid, Foxa2 and HNF1a are excluded from the nucleus, by a mechanism that can be 
inhibited by the antioxidant N-acetylcysteine (NAC), suggesting that reactive oxygen species 
(ROS), produced as a result of lipid catabolism, are engaged in this process. Nuclear exclusion of 
the transcription factors reduces GnT-4a and Glut2 expression, as well as the normal glycosylation 
of Glut2, leading to transporter internalization, reduced cell-surface expression, and reduced GSIS. 
This results in glucose intolerance, insulin resistance, and hepatic steatosis. These deregulations can 
be prevented by transgenic overexpression of Mgat4a and Slc2a2 (Ohtsubo et al., 2011; Thorens, 
2011). 
18. Inflammasomes activation following glucotoxicity / lipotoxicity 
Another mechanism contributing to 
inflamm-aging/metaflammation is 
the activation of the intracellular 
inflammasomes.  
It has been proposed a model for IL-
1beta-induced inflammation in 
response to diabetes-associated 
DAMPs (Shin et al., 2015). Long-
lasting exposure of macrophages or 
pancreatic cells to elevated levels of 
glucose and palmitate boosts NLRP3 
activation through a mechanism that 
involves ROS and TXNIP 
activation, resulting in an increased 
production of mature IL-1. In 
Figure 16. The absence of glycosylation of Glut2 in mice fed with high fat 
diet impairs insulin secretion 
Figure 17. Inflammasomes activation in glucotoxicity/lipotoxicity 
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addition, palmitate stimulates the expression of IL-1 through NF- B activation via TLR4. Ceramide 
can also trigger the processing of pro-IL-1 into its mature form through NLRP3 activation in 
macrophages. IAPP secreted from cells aggregates into insoluble islet amyloid deposits and is 
internalized by macrophages, inducing NLRP3 activation and the production of mature IL-1. 
Endocannabinoids (ECs) also promote NLRP3 activation and IL-1 production via CB1R. RAGE 
and its ligands (AGE, HMGB1, S100 protein, and IAPP) can enhance IL-1 expression and beta-cell 
death. Deleterious levels of IL-1 induce beta-cell death and deregulate insulin receptor (IR) 
signaling, potentially leading to insulin resistance in insulin target cells (revised from Shin et al., 
2015). 
19. Endoplasmic reticulum stress response 
Endoplasmic reticulum is a well-known target organelle for inducing inflammation (figure 19, 
extracted from Gregor and Hotamisligil, 2011). There have been reported three different ER stress 
pathways leading to inflammation, deriving from the ER’s unfolded protein response (reviewed 
from Gregor and Hotamisligil, 2011). IRE-1 uses its 
kinase domain partnering with TRAF2 to activate the 
inflammatory kinases JNK and IKK; this leads to 
upregulation of inflammatory mediators via the 
transcription factors AP-1 and NF-κB, respectively. 
IRE-1 splicing of XBP1 mRNA also triggers 
inflammatory consequences, as XBP1 has been shown 
to regulate inflammatory cytokine stimulation and 
immune responses in various cell types, especially 
macrophages. PERK activation results in decreased 
translation of IκBα, a suppresor of NF-κB signaling, 
thereby augmenting NF-κB transcriptional activity. In 
addition, PERK activation mediates ATF-4 translation, 
and ATF-4 was shown to regulate inflammatory 
cytokine induction, although the mechanism remains 
unknown. PKR is also activated by ER stress and 
contributes to JNK and IKK activation. Finally, ATF-6 
has also been demonstrated to increase NF-κB 













19. Extracellular biological roles of glycans: focus on inflammation (IgG 
glycosylation)  
20. Antibody glycosylation controls antibody activity 
Each IgG has an N-glycan 
attached at Asn297 in the 
polypeptide chain of each 
heavy part (figure 19, 
modified from Higel et al., 
2016); since the constant 
Fc region of the heavy 
chains defines the capacity 
of the antibody to interact 
with Fc receptors, the IgG 
immune response can be 
measured as a function of 
the interaction between 
IgG N-glycan composition 
and Fc receptor type 
(Higel et al., 2016). There are two major groups of Fc receptors: classical (FcϒRI, FcϒRIIa, 
FcϒRIIb, FcϒRIIc, FcϒRIIIa, FcϒRIIIb) and non-classical (C-lectin-type receptor DC-SIGN, 
FcRn) (Winkel and Anderson, 1991). It is interesting to note that 70% of human IgGs are 
asymmetrically glycosylated (being both Fc chains always glycosylated, while the Fab regions are 
glycosylated only in 20% of IgGs), and that the addition and removal of sugars (galactose, fucose, 
b-GlcNAc, or sialic acid) are directly linked to altered antibody functionality (Higel et al., 2016; 
Jennewein and Alter, 2017). In this line, it has been described that: removal of fucose enhances IgG 
affinity for FcϒRIIIa and thus it boosts antibody-dependent cellular cytotoxicity (ADCC) (Seeling 
et al., 2017), exposed bisecting GlcNAc residues (“G0”) also promote ADCC (Seeling et al., 2017), 
fucosylation and bisection are largely mutually exclusive (Seeling et al., 2017), removal of 
galactose either increases or decreases affinity for FcϒR (depending on specific FcϒR receptor and 
IgG subclass), and presence of sialic acids has been linked to anti-inflammatory effects as they 
decrease binding to FcϒRIII receptors (Seeling et al., 2017). 
21. Glycovariation in physiological and pathological conditions 
Glycosylation is a highly ordered and conserved process. However, disease-associated changes (e.g 
autoimmune or infectious diseases) suggest that it is actively modulated during inflammatory 
responses. The specific mechanisms leading to this variation in glycosylation, though, are 
incompletely understood. Nevertheless, some factors that shape antibody glycosylation have been 
proposed (reviewed from Zhou et al., 2018):  
- Glycosyltransferase/glycosidase expression 
- Shifts in monosaccharide availability 
- ER stress 
Figure 19. Antibody glycosylation controls antibody activity 
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- Golgi pH and organization 
- Kinetics of protein production 
- Availability of vesicular transport machinery  
22. Aberrant antibody glycosylation in ageing and disease: the egg or the chicken? 
In this subsection, I modestly disclosure the most important research questions related to my 
investigation. 
What comes first: metaflammation or inflamm-aging? (Figure 20) Do they become an unavoidable 
unbreakable dichotomy in the long run? In other words, are older patients (>60 years old), already 
exhibiting a low-grade pro-inflammatory phenotype and with more abundance of agalactosylated 
glycans species, more prone to metaflammation and other pathophysiological changes in protein 
glycosylation? Do N-glycan species related to inflamm-aging differ from N-glycan species related 
to metaflammation? There is some evidence in literature that this might be the case (see next 
subsection). Although more studies are needed, considering this starting point, another question 
comes up: are glycans the cause or the consequence of metaflammation and/or inflamm-aging?  
Rheumatoid arthritis (RA) and the human immunodeficiency virus (HIV) are two examples that aid 
to provide a better insight to these questions. In the case of RA, loss of galactosylation on IgG1 
appears in circulation before onset, shortly after the development of anti-citrullinated (CCP) 
antibodies (Ercan et al., 2010); therefore, in RA, the sequence of events apparently is 1) auto-
antibodies, 2) loss of galactosylation, 3) onset of disease, pointing to that glycans are the 
consequence of RA disease. In HIV, it has been demonstrated that spontaneous controllers (low to 
undetectable viral replication) without retroviral therapy, maintain the highest levels of 
agalactosylated antibodies (reviewed from Zhou et al., 2018), which suggests that in HIV glycans 
are also the consequence of the disease. 
In the case of metaflammation and glycosylation, the answer to what is first is intuitive, as the 
question becomes too simplistic, due to the complexity and heterogeneity of the disease. Thus, it 
should be reformulated: do N-glycans change over the course of preclinical (that is, insulin 
resistance and impaired insulin secretion) to clinical diagnoses (obesity and/or T2D, T2D 
complications, metabolic syndrome)? 
 
Figure 20. What comes first in RA, HIV and metabolic syndrome, disease or inflammation? 
46 
 
23. Advanced glycation end products / HbA1c: surrogate biomarkers of N-glycans in 
T2D? 
Though further research is needed to answer the posed research questions concerning N-glycans 
species as disease trackers, specifically in T2D, it has been shown that the so-called advanced 
glycation end products (AGEs) do precede diabetes mellitus (Vlassara and Striker, 2011). AGEs are 
a heterogeneous family of sugar-amino acid adducts formed by a nonenzymatic covalent binding of 
reducing sugars to protein amino groups. 
Vlassara and Striker postulated that current processed 
food contains appetite-enhancing AGEs, that prompt 
food consumption and overnutrition, which in the long-
term lead to increased BMI, obesity and diabetes 
mellitus, as well as oxidant overload. Steady influx of 
nutrient AGEs and advanced lipoxidation end products 
(ALEs) leads to suppression of innate host defenses and 
an overflow of intracellular ROS, which increases the 
basal oxidant stress and inflammation (reviewed from 
Vlassara and Striker, 2011). The interaction of these 
processes can simultaneously cause β-cell dysfunction, 
impaired insulin secretion and insulin resistance, as well 
as diabetic complications. Restriction of food-derived 
AGEs reduces oxidative stress and prevents or improves 
type 1 and type 2 diabetes mellitus in mice (figure 21, 
extracted from Vlassara and Striker, 2011).  
The most studied glycated protein is glycated hemoglobin (or HbA1c), which, indeed, has been 
shown to display a strong association with AGEs. As mentioned in the general introduction, HbA1c 
serves as indicator of long-term glycaemia (average lifespan of red cells is of 4 months). In 2010, 
the American Diabetes Association (ADA) added HbA1c as a further diagnostic criterium for 
diabetes and prediabetes in an attempt to shorten the diagnosis time of T2D (the average time 
between onset and diagnosis of T2D is 7 years) and as a marker of glycaemic control in established 
patients – in T2D individuals, the rate of formation of HbA1c is a direct function of the average 
blood glucose concentration – (Gillett, 2009; American Diabetes Association 2010). In this regard, 
we wondered whether a combination of N-glycans would predict the T2D status better than HbA1c 
alone (see aims of thesis below), considering a) the nature of the bond type (non-enzymatic in N-
glycans vs enzymatic in HbA1c), and b) the origin of bond formation (mostly intracellular in N-
glycans vs extracellular in HbA1c).  
 
20. N-glycans as biomarkers in liver diseases, aging, and age-related diseases 
In this section, I review major studies conducted in aging and (the underlying diseases that give rise 
to) metabolic syndrome which use N-glycans as candidate biomarkers. 




24. Liver diseases 
Most of plasma proteins, and thus N-glycans (Apweiler et al., 1999), are synthesized in the liver and 
pancreas (Uhlén et al., 2015), whereas immunoglobulins are synthesized specifically in cells of the 
immune system (Rhoades and Pflanzer, 2002). Particularly, liver is not only an important source of 
glycoproteins generation, but also a metabolic organ. Thus, it is worthy to focus on liver diseases to 
better understand N-glycan profiling of age-related diseases (e.g. T2D or obesity). In this line, a 
bunch of literature has extensively reported the characteristic derived glycan traits (i.e. N-glycan 
features: sialylation, galactosylation, bisection, fucosylation) and the implicated enzymes in liver 
pathologies (figure 22, extracted from Takahashi et al. (2016).  
 
Figure 22. Glycosyltransferases enzymes 
 
Figure 23. Summary of main findings regarding alteration of glycosylation in liver pathologies 
3. Alcoholic liver disease 
In alcoholic liver disease (ALD), haptoglobin, α1-acid glycoprotein, α2-HS glycoprotein, and 
transferrin are known to exhibit an increased branching. The Golgi apparatus plays an essential role 
in the alteration of glycosylation patterns in all liver diseases. In ALD, there is a characteristic 
significant accumulation of hepatic protein caused by impaired glycosylation and glycoprotein 
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trafficking. A proposed explanation for the diminished Golgi functioning is the deficient 
polymerization of microtubular protein as a downstream consequence of hepatic acetaldehyde due 
to ethanol oxidation. In an experimental rat model of ALD by Gosh et al., it was described a 
decreased activity of the mannosyltransferase and galactosyltransferase enzymes, a lowered 
intracellular dolichol concentration, and a strong decreased synthesis and activity of ST6GalI. The 
authors also reported an increase of 30% in liver weight as compared to the body weight of that rat 
model, which was attributed to the accumulation of hepatic lipids and proteins leading to fatty liver 
and steatosis. In this research, they also studied O-glycosylation in Apo E, which showed, as in N-
glycosylation, a decrease in mannosylation and sialylation. The relative ratio of labeled sugar to 
leucine incorporation (glycosylation index) revealed a 50% reduction in relative mannosylation of 
Apo E at both the microsomal and the Golgi level. The impairment in the glycan structures of Apo 
E was hypothesized to be responsible for the defective clearance of HDL and VLDL, resulting in a 
defective cholesterol transport to the liver and the subsequent hepatic accumulation (reviewed from 
Blomme et al., 2009; Callewaert et al., 2004). 
4. Fatty liver diseases 
At least two different studies investigated the impact of aberrant glycosylation by overexpressing 
N-acetylglucosaminyltransferase (GnT) III in transgenic mice. An increased GnT-III activity results 
in an increased level of bisecting GlcNAc in Apo B, which impairs the glycoprotein functionality 
by preventing its release in bloodstream, and thus its accumulation in the liver. Not only Apo B 
concentrations were significantly elevated in the liver, but also Apo A1. These studies point to that 
N-glycans can have an important impact on lipid metabolism (reviewed from Blomme et al., 2009; 
Callewaert et al., 2004). 
Not only GnT-III, but also the ectopic expression of α1,6-fucosyltransferase (α1,6-FT) causes 
steatosis in the liver and the kidney (reviewed from Blomme et al., 2009; Callewaert et al., 2004). 
The increased expression of this enzyme lowered the activity of the lysosomal acid lipase (LAL), 
the accumulation of which might contribute to the lipid accumulation observed in the lysosomes of 
the liver.  
5. Hepatocellular carcinoma and cirrhosis 
Alteration of glycosylation has also been documented in malignant cellular transformation. In 
hepatocellular carcinoma (HCC), three glycosyltransferases are considered crucial: GnT-V, GnT-III 
and α1,6-FT. GnT-V is coded on the MGAT5 gene, which is regulated by the Ras signaling pathway 
(commonly up-regulated in cancerous cells). Though GnT-III and GnT-V compete for the same 
substrate, the bisecting GlcNAc, and the activity of both enzymes is increased in HCC, the activity 
of GnT-III is more prominent; on the other hand, GnT-V is directly associated with metastasis.  
In HCC, the activity of ST6GalI is increased, in contrast to ALD, in which is decreased. But the 
best known biomarker in HCC is the elevated serum concentration of fucosylated α-fetoprotein 




25. Type 2 diabetes mellitus 
Table 3 shows a summary of collected literature about major glycomic biomarkers findings in T2D. 
As a whole, the studies report increased levels of N-glycan branching (Testa et al., 2015; Keser et 
al., 2017; Adua et al., 2018) in whole plasma glycome. Regarding sialylation, there is controversy: 
two observational studies show a reduction in levels of sialylation (Lemmers et al., 2017; Dotz et 
al., 2018) in the IgG plasma N-glycome of T2D patients, measured with MALDI-TOF, and an 
experimental analysis by Tanigaki et al. (2018) demonstrated that IgG hyposialylation in mice 
promotes obesity-induced insulin resistance. Conversely, Keser et al. (2017) revealed an increase in 
trisialylated glycans in whole plasma N-glycome of patients with hyperglycaemia, Liu et al. (2019) 
also evinced increased levels of sialylation whole plasma N-glycome in an Uyghur population of 
T2D patients. With respect to digalactosylated structures, Adua et al. (2018) and Testa et al. (2015) 
report decreased levels, while Liu et al. (2019) shows an increase in bigalactosylation. There are 
also divergent results with regard to bisecting GlcNAc structures: Lemmers et al. (2017) shows an 
increase while Liu et al. (2019) shows a reduction.  
The causes of divergencies between studies should be deeply analyzed in each case, but possible 
sources are: technology used for the collection of N-glycans, IgG or whole N-glycome, small 
sample size, lack of randomization, unbalanced number of cases vs controls, poor variables 
matching in case-control studies, confounders not considered (thus, structure present in the data that 
explain the results), possible batch effects, different normalization techniques, models used for the 
analyses and the covariates employed. 
Table 3. Summary of the major glycomic signatures of T2D described in literature 
Set up  Analysis Overview Main results Reference 
MALDI-TOF 
70 N-glycans, 96 derived traits 
IgG plasma N-glycome  
Discovery cohort:  
1583 cases, 728 controls. 
Replication cohort:  
232 cases, 108 controls. 
Logistic regression models: 
Model1 = Group ~ N-glycans + 
Sex + Age + Sex*Age 
Model2 = Model1 + BMI 
Model3 = Model2 + HDLc + 




Dotz et al., 2018 
MALDI-TOF  
70 N-glycans, 96 derived traits, 
IgG plasma N-glycome 
Discovery cohort:  
DiaGene:  
N=1886 cases, N=854 controls 
3 Replication cohorts: 
CROATIA-Korcula  
1. Logistic regression models 
(in each of the 4 cohorts): 
Model1 = Group ~ N-glycans + 
Sex + Age + Sex*Age 
Model2 = Model1 + BMI 
Model3 = Model2 + HDLc + 
nonHDLc + smoking 
2. Meta-analysis of the 4 
cohorts: weighted z-transform 
IgG in T2D: 
↓galactosylation  
↓sialylation 
↑bisection of fucosylated 
structures 





N=162 cases, N=3162 controls  
method, 
Bonferroni correction for 
multiple testing 
3. Logistic regression models 
for prediction analyses  
HILIC-HPLC  
46 N-glycans, 12 derived traits, 
Whole plasma N-glycome 
Case/control study: 
Cases: hyperglycaemic  
Controls: normoglycaemic  
Casos or controls with critical 
illness are considered to have 
higher risk for T2D. 
Discovery cohort:  
N=59 cases, N=49 controls 
Test cohort: 
N=52 cases, N=14 controls 
3 Replication cohorts: 
FinRisk population: 
N=37 T2D, N=37 controls 
ORCADES:  
N=94 cases with ↑[HbA1c], 
N=658 controls 
SABRE: 
N=307 cases with ↑[HbA1c], 
N=307 controls 
Analyses of associations 
between clinical trait of interest 
and glycan measurements were 
performed using a regression 
model with age and sex 
included as additional 
covariates.  






↓neutral glycans  
↑trisialylated  
glycans  
Keser et al., 2017 
UPLC 
39 N-glycans 
Total plasma N-glycome 
Case cohorts from the Prospective 
EPIC - Potsdam cohort 
(n=27548): 
Incident cases of T2D (N=5820; 
median follow-up time 6.5 years)  
Cases of CVD (N=5508; median 
follow-up time 8.2 years) 
1. N-glycan data were adjusted 
for age by applying multiple 
fractional polynomial (MFP) 
regression separately in men 
and women. The age-adjusted 
residuals were used to construct 
an N-glycan score to predict 
type 2 diabetes with machine 
learning techniques. 
2. The score was validated in an 
independent cohort and used in 
6 different models to assess the 
ability of different predictors to 
The N-glycan–based type 
2 diabetes score was 
strongly predictive for 
diabetes risk (weighted C-
index 0.83, 95% CI 0.78–
0.88). 
N-glycans were 
moderately predictive for 
CVD incidence (weighted 
C indices 0.66, 95% CI 
0.60–0.72, for men; 0.64, 
95% CI 0.55–0.73, for 
women).  
Wittenbecher et al., 2020 
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predict type 2 diabetes. 
4. Selection of potential CVD-
specific predictors was 
conducted analogous to the 
selection of diabetes-related N-
glycans with machine learning 
techniques, deriving a weighted 
score. 
DSA-FACE  
10 Whole serum N-glycans 
Italian cohort: 
N=562 T2D, N=599 healthy 
controls 
1) Comparison of serum N-
glycan profiles in T2DM, 
without and with complications, 
2) association of N-glycans with 
diabetic complications, 
3) associations with MetS, 
4) correlation of N-glycans 
profiling with MetS parameters 
↓Monogalactosylated, 
core-fucosylated 
diantennary N-glycans in 
T2D compared with 
controls 
Testa et al., 2015 
HILIC-UPLC 
Total plasma N-glycome  
39 N-glycans and 22 derived traits 
Cohort: 
Ghana population 
N=232 cases, N=219 controls 
Association between N-glycans 
and age in both males and 
females for cases and controls, 
determined by linear regression, 
and multiple testing adjustment 
with Benjamini-Hochberg 
method to control FDR 











Adua et al., 2018 
HILIC-UPLC  
IgG plasma N-glycome 
24 N-glycans  
Case-control Australian 
population cohort: 
N=217 cases, N=632 controls 
1) logistic models: disease 
status ~ IgG glycan traits + 
covariates (age, sex, BMI, 
WHR, SBP, and DBP), multiple 
testing with Benjamini-
Hochberg procedure;  
2) classification model based on 
the significantly altered glycans 
to evaluate the potential of IgG 
N-glycans as T2D biomarkers 
Two directly measured and 
four derived glycan peaks 
were significantly 
associated with T2DM. 
Li et al., 2019 
HILIC-UPLC  
IgG subclass Fc N-
glycopeptidome plasma/serum 
(unknown)   
1. Associations between IgG 
subclass-specific Fc N-
glycopeptide profiles and 
disease status were performed 
using logistic regression, 
adjusting for risk factors for 
27 directly measured and 4 




Liu et al., 2019 
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24 N-glycans  
Case-control Uygur population 
cohort: 
N=115 cases, N=122 controls 
T2DM covariates; 
2.  LASSO to select IgG 
subclass-specific Fc N-glycans; 
3. Model evaluation 
with T2DM. 
IgG2 in T2DM:  
↓bisecting GlcNAc 
↑digalactosylation  




Human and transgenic C57BL/6J 
mouse pancreatic beta cells  
Experimental analyses in human 
and mice beta pancreatic cells 
to: induction of molecular 
events by exposure of elevated 
levels of free fatty acids (FFA) 
or by administration of high-fat 
diet associated with obesity  
↑[FFA] caused nuclear 
exclusion and ↓expression 
of the transcription factors 
FOXA2 and HNF1A in 
beta cells; 
this resulted in a deficit of 
GnT-4a 
glycosyltransferase 
expression in beta cells 
that produced 
signs of metabolic disease, 
including hyperglycemia 
Ohtsubo et al., 2011 
Male C57BL/6 WT, 
FcγRIIB–/–, Fcγ–/–, B–/–, SAP–/–, 
FcγRIIBfl/fl and VECad-Cre mice, 
or in offspring from their mating  
Experimental analyses ↓IgG sialylation in mice is 
implicated in obesity-
induced insulin resistance 
Tanigaki et al., 2018 
 
26. Aging research 
Table 4 shows a summary of collected literature about major glycomic biomarkers findings in 
aging. In general, studies agree in the fact that over age there is a progressive decrease in 
bigalactosylated species that goes along an increase of agalactosylated species. 
Table 4. Summary of the major glycomic signatures of aging described in literature 
Set up  Analysis Overview Main results Reference 
HILIC and WAS HPLC 
33 IgG plasma N-glycome 
population-based study of 
N=1914 individuals from Vis 
and Korkula 
Multiple linear regression 
used to analyze the association 
of selected predictor variables 
and each glycan feature 
F2, G0, G2, S2, A2 glycan 
traits: age-dependent 
↑galactosylation correlate with 
lipid status 
Knezevic et al., 2010 
DSA-FACE  GlycoAge test definition GlycoAgeTest:  -Significantly 
↑in dementia patients 
Vanhooren et al., 2010 
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10 whole serum N-glycan  
Participants: 
N=425 healthy Belgian adults  
N=84 Italian centenarians 
N=79 with dementia  
N=6 Cockayne Syndrome 
(CS) 
compared with age-matched 
controls. 
-Highly heterogeneous in CS, 
but even the lowest value is 
much higher than in the 
controls 
HILIC-HPLC  
26 whole plasma N-glycans 
N=2396 middle aged 
participants in the Leiden 
Longevity Study (LLS) 
Regression strategies applied 
to evaluate associations 
between glycan patterns, 
familial longevity, and healthy 
aging. 
↑A2G2: associated with 
healthy ageing (longevity) 
↓A2G1S1: associated with 
occurrence of myocardial 
infarction 
Ruhaak et al., 2011 
UPLC 
24 IgG plasma N-glycans 
Participants:  
N=906 Vis island 
N=915 Korčula island 
N=2035 Orkney islands 
N=1261 TwinsUK 
A predictive model of age was 
built (“GlycanAge”) 
IgG N-glycans markers of age: 
FA2B, FA2G2, and FA2BG2, 
explaining 58% variance 
Kristic et al., 2014 
MALDI-TOF-MS 
12 tryptic IgG1 and IgG2 Fc 
glycopeptides 
N=1967 participants in the 
LLS 
Several regression strategies 
were applied to evaluate the 
association of IgG 
glycosylation with age, sex, 
and longevity 
Galactosylated glycoforms: 
↑bisecting GlcNAc with age. 
Sex-related differences below 
60 years: younger females had 
higher galactosylation, which 
↓stronger with age 












5. MATERIALS AND METHODS 
This section, following the general description of materials and methods, describes the algorithm 
used in the analyses, that is two-way orthogonal partial least squares (O2PLS) (figure 24):  
 
Figure 24. Two-way orthogonal partial least squares algorithm 
O2PLS is a dimension reduction technique that decomposes the variance of 2 data sets in 3 parts 
(Bouhaddani et al., 2016): 
• Joint part: biologic variance common to both data sets (clinical and N-glycans). 
• Single-omics specific part: the variance specific to each data set. 
A critical point for identifying the joint and the specific parts is to choose the number of joint and 
specific principal components (PCs) through 1) the elbow technique by the visualization of the 
eigenvalues plot, and 2) cross-validation. The analyses were done with the OmicsPLS package. 
Since in this thesis dissertation, a high number of O2PLS models were performed, the number of 
PCs was chosen only by cross-validation, by selecting the combination of joint and specific PCs 









The general aims of this study are:  
1. To assess whether N-glycans predict diabetic or non-diabetic status better than the HbA1c. 
2. To identify the major sources of variation both in Phenomics and Glycomics in four age 
ranges in six groups of individuals (Ctrl F, Ctrl M, PreDiab F, PreDiab M, Diab F, Diab M) 
and to identify whether such sources of variation correspond to major biological conditions 
(e.g. prediabetic or diabetic status, metabolic syndrome).  
3. To visualize the integrated weights (i.e. loading values) and mean values of both data sets. 
The specific for this study are: 
1. To perform a logistic model by modelling a binary outcome composed of controls (N=285) 
and diabetics (N=555) as function of HbA1c or as function of N-glycans. 
2. To identify covariating N-glycan species and endophenotypes characteristic across different 
age ranges and per sex by considering N=288 controls (FIRB cohort) – individuals with 
normal ranges of HbA1c, insulin, HOMA and fasting glucose –, N=310 prediabetics and 
N=557 diabetics – individuals with abnormal ranges of HbA1c, insulin, HOMA and fasting 
glucose –. This will be achieved by performing O2PLS models on two data sets, one 
composed of 44 clinical variables (excluding sex, as it does not follow a normal 
distribution) and another one composed of 10 N-glycans, in each of 4 predefined age ranges 
(20-44, 45-55, 56-70, 71-85 years) and in the full age range (20-85 years) in Ctrl and, due 
to smaller sample sizes, 3 age ranges in PreDiab and in Diab (45-55, 56-70, 71-85 years), 
separately in males and females (total of 23 O2PLS models).  
3. To generate line plots of the integrated weights (i.e. loading values) and mean values for the 
most relevant clinical variables and N-glycans to detect patterns taking place at specific age 














21. Demographic characteristics of the cohort 
The characteristics of the participants included in the study are described in Table 5 and Table 6. 
Table 7 illustrates the number and the frequency of individuals that take medication.  
Table 5. Patients baseline characteristics 
Variable Ctrl F 
(n=177) 










mean Sd mean sd mean sd mean Sd mean Sd mean sd 
Azotemia 
(log U) 
36.38 8.97 40.83 12.56 38.19 9.67 39.22 8.4 40.26 13.89 40.25 10.27 
Age (years) 56.4 13.21 65.14 8.27 60.44 11.52 60.24 10.14 66.6 7.73 56.39 12.44 
BMI (kg/m2) 25.75 4.81 28.32 4.29 27.75 5 27.71 3.5 29.66 5.16 27.17 4.23 




87.2 6.28 165.6 48.75 96.16 10.85 100.9 8.97 160.83 48.72 89.22 5.59 
HbA1c (%) 5.43 0.36 7.41 1.3 5.93 0.3 5.82 0.31 7.5 1.22 5.35 0.21 
Cholesterol 
(mg/dL) 
218.26 38.8 196.73 35.27 221.53 35.35 210.46 36.32 218.88 37.52 204.33 36.45 
HDL 
(mg/dL) 
64.24 13.92 48.72 11.88 60.19 13.92 51.61 13.55 56.68 16.41 50.18 11.81 
EGFR 
(mL/min) 
87.14 20.35 80.38 19.86 83.53 17.96 90.77 25.8 76.47 21.25 95.16 26.02 
Fibrinogen 
(mg/dL) 
289.5 73.05 296.41 81.01 306.91 77.08 269.5 67.28 315.33 79.98 267.19 84.21 
PAI1 
(ng/mL) 
19.28 10.23 19.56 8.99 22.3 11.14 23.45 12.4 22.41 10.3 25.01 12.24 




0.67 0.26 0.73 0.31 0.61 0.25 0.79 0.37 0.62 0.24 0.79 0.35 
LDL 
(mg/dL) 
125.04 34.34 110.8 28.13 126.15 29.79 122.78 30.08 123.12 32.67 120.98 30.73 
Apo A1 
(mg/dL) 
186.22 29.68 159.01 31.39 183.99 29.05 168.04 31.68 178.24 34.88 167.64 27.1 
Apo B 
(mg/dL) 
97.47 27.9 98.24 26.15 103.05 27.77 103.92 27.67 105.57 26.58 100.38 28.87 
Total Iron 
(mcg/dL) 
79.64 27.77 86.45 27.94 78.47 24.15 82.74 31.38 78.63 25.15 84.05 33.5 
Transferrin 
(mg/dL) 
255.44 44.75 259.24 37.46 261.49 42.71 258.55 38.09 270.58 47.05 262.99 48.11 
Total Protein 
(g/dL) 
7.12 0.43 7.25 0.52 7.03 0.49 7.09 0.45 7.15 0.49 7.2 0.47 
White Cells 
(n/mm3) 
5.97 1.59 6.58 1.57 6.06 1.34 6.45 1.56 6.8 1.65 6.3 1.69 
Red Cells 
(n/mm3) 
4.56 0.39 4.83 0.44 4.53 0.36 4.97 0.36 4.57 0.42 4.96 0.44 




MCV (fL) 88.12 5.31 88.84 5.13 88.82 5.22 88.5 5.06 87.84 5.45 88.77 5.1 
Platelets 
(n/mm3) 
237.81 51.24 199.59 54.53 241.07 58.34 215.73 50.99 239.07 63.57 213.78 57.77 
MPV (fL) 11.12 0.98 11.21 0.96 11.11 1.01 11.1 0.85 11.11 0.96 11.17 0.98 
Neutrophils 
(CLR U) 
2.1 0.4 2.12 0.33 2.06 0.37 2.05 0.35 2.17 0.33 2.09 0.41 
Lymphocytes 
(CLR U) 
1.65 0.32 1.49 0.31 1.57 0.32 1.54 0.33 1.6 0.31 1.54 0.36 
Eosinophils 
(CLR U) 
-0.98 0.52 -0.86 0.53 -0.93 0.5 -0.84 0.52 -0.93 0.49 -1 0.52 
Monocytes 
(CLR U) 
-0.07 0.26 -0.1 0.3 -0.09 0.3 -0.03 0.27 -0.14 0.28 0 0.33 
Creatinine 
(log U) 
0.73 0.14 1.01 0.32 0.74 0.14 0.91 0.22 0.82 0.28 0.89 0.21 
Uric Acid 
(log U) 




70.98 19.66 72.58 21.74 73.4 22.1 71.43 20.77 82.51 26.97 74 18.68 
AST (log U)  20.35 5.33 22.55 10.02 21.4 7.45 23.25 10.35 21.61 12.29 25.43 13.21 
ALT (log U) 35.79 8.47 44.7 17.14 39.3 15.06 42.63 14.83 41.66 15.04 42.17 12.19 
Triglycerides 
(log U) 




5.7 3.61 6.94 6 6.98 5.65 7.76 7.36 7.22 4.84 6.48 4.18 
HOMA 
(pow. 0.3 U) 
1.22 0.79 2.95 3.12 1.7 1.56 1.87 2.04 2.9 2.41 1.42 0.88 
CRP (pow. 
0.275 U) 
2.94 3.67 4.46 8.85 4.17 6.71 3.06 4.29 5.07 7.02 3.71 9.9 








0.5 0.2 0.43 0.22 0.45 0.18 0.46 0.19 0.45 0.19 0.48 0.16 
SDMA (sqrt 
U) 
1 0.57 0.9 0.61 0.96 0.5 1.11 0.67 0.91 0.65 1.1 0.65 
ADMA (sqrt 
U) 
1.01 0.6 1.04 0.56 1.04 0.51 1.07 0.67 1.09 0.61 0.92 0.5 
RDW-CV 
(log U) 
13.4 1 13.17 0.73 13.48 0.84 13.34 0.8 13.52 1.03 13.3 0.94 
Log U: log transformed units; pow. 0.125/0.275/0.3 U: raise to the power of 0.125/0.275/0.3 transformed units; sqrt U: 
square root transformed units; CLR U: centre-log ratio transformed units; BMI: body mass index; WHR: waist to hip ratio; 
HbA1c: glycated haemoglobin; HDL: high-density lipoprotein; EGFR: estimated glomerular filtration rate; PAI1: 
plasminogen activator 1; TAFI: thrombin activatable fibrinolysis inhibitor; LDL: low-density lipoprotein; Apo A1/B: 
apolipoprotein A1/B; MCV: mean corpuscular volume; MPV: mean platelets volume; CRP: C reactive protein; GGT: 
gamma glutamyl transpeptidase; SDMA: symmetric dimethylarginine; ADMA: asymmetric dimethylarginine; RDW-CV: 









Table 6. Number and frequency of individuals that are affected by clinical conditions 
Clinical History  Ctrl F 
(n=177) 










Metabolic Syndrome (ATPIII) 12 (7%) 7 (6%) 37 (20%) 14 (11%) 190 (73%) 140 (47%) 
Metabolic Syndrome (IDF) 15 (8%) 15 (14%) 59 (32%) 33 (27%) 201 (78%) 180 (60%) 
Bypass 2 (1%) 2 (2%) 0 1 (1%) 10 (4%) 39 (13%) 
Somatic Neuropathy 0 0 0 0 35 (14%) 67 (22%) 
Nephropathy 0 0 0 0 24 (9%) 48 (16%) 
Chronic Renal Insufficiency 0 0 0 0 5 (2%) 15 (5%) 
Retinopathy 0 0 0 0 72 (28%) 82 (28%) 
Arteriopathy Obliterans of Lower 
Limbs 
0 0 0 0 14 (5%) 21 (7%) 
Arteriopathy Obliterans of Upper 
Limbs 
0 0 0 0 10 (4%) 16 (5%) 
Cardiac Ischemia 0 0 0 0 37 (14%) 62 (21%) 
Major Adverse CDV Events 6 (3%) 1 (1%) 3 (2%) 6 (5%) 26 (10%) 58 (19%) 
 
Table 7. Number and frequency of individuals that take medication 
Medication Ctrl F 
(n=177) 










ACE Inhibitors 29 (16%) 10 (9%) 37 (20%) 19 (16%) 120 (46%) 113 (38%) 
Anti-inflammatories 7 (4%) 4 (4%) 12 (6%) 12 (10%) 55 (21%) 90 (30%) 
Bisphosphonates 9 (5%) 0 6 (3%) 0 5 (2%) 3 (1%) 
Anti-arrythmics 2 (1%) 1 (1%) 1 (1%) 4 (3%) 18 (7%) 18 (6%) 
Calcium-Antagonists 8 (5%) 6 (6%) 14 (7%) 11 (9%) 49 (19%) 86 (29%) 
Beta-blockers 12 (7%) 7 (6%) 15 (8%) 9 (7%) 48 (19%) 56 (19%) 
Fibrates 0 1 (1%) 1 (1%) 1 (1%) 9 (3%) 4 (1%) 
Statins 9 (5%) 8 (7%) 17 (9%) 8 (7%) 55 (21%) 53 (18%) 
Metformin 0 0 0 0 108 (42%) 96 (32%) 
Sulphonylureas 0 0 0 0 122 (47%) 146 (49%) 
Glinides 0 0 0 0 5 (2%) 8 (3%) 
Insulin Administration 0 0 0 0 52 (20%) 48 (16%) 
Vasodilators 1 (1%) 2 (2%) 2 (1%) 2 (2%) 21 (8%) 30 (10%) 
Anti-aggregants 5 (3%) 11 (10%) 8 (4%) 6 (5%) 43 (17%) 55 (18%) 
Diuretics 11 (6%) 1 (1%) 10 (5%) 4 (3%) 35 (14%) 30 (10%) 
Gastroprotectors 15 (8%) 6 (6%) 12 (6%) 4 (3%) 22 (8%) 23 (8%) 
Micronutrients 12 (7%) 3 (3%) 12 (6%) 1 (1%) 22 (8%) 13 (4%) 
Antibiotics 3 (2%) 1 (1%) 1 (1%) 0  4 (2%) 4 (1%) 
SNC Medication 23 (13%) 2 (2%) 24 (13%) 2 (2%) 32 (12%) 22 (7%) 
Thyroid Medication 14 (8%) 2 (2%) 13 (7%) 5 (4%) 14 (5%) 4 (1%) 
Lipid Therapy 9 (5%) 11 (10%) 18 (10%) 9 (7%) 65 (25%) 58 (19%) 
Glycaemia Therapy 0 0 0 0 195 (75%) 224 (75%) 
59 
 
Hypertension Therapy 44 (25%) 21 (19%) 63 (34%) 30 (25%) 162 (63%) 174 (58%) 
Presence Therapy 91 (51%) 34 (31%) 106 (57%) 43 (35%) 240 (93%) 273 (92%) 
 
22. Prediction of (non-)diabetic status by HbA1c and by N-glycans 
May N-glycans predict T2D status than the classic HbA1c? To answer that I performed two logistic 
models, one using HbA1c as predictor and N-glycans for the other model. The total N was of 840 
individuals. The areas under the curve (AUC) and the confusion matrixes of the following models 
evidence that HbA1c predicts diabetic or non-diabetic status far better than the 10 N-glycans. 
Confidence intervals (CI) for the AUC were generated by bootstrapping, using an α=10%. 
Model 1: Ctrl/Diab ~ HbA1c 
AUC=0.979 (0.970-0.988) 
Table 8. Confusion matrix for HbA1c 
 Expected Ctrl Expected Diab 
Observed Ctrl 277 8 
Observed Diab 31 524 
 
Model 2: Ctrl/Diab ~ 10 N-glycans 
AUC=0.706 (0.782-0.843) 
Table 9. Confusion matrix for 10 N-glycans 
 Expected Ctrl Expected Diab 
Observed Ctrl 159 126 
Observed Diab 81 474 
 




Figure 25. Decomposed parts of the O2PLS integrations between 44 clinical variables and 10 N-glycans in 
four different age ranges by groups and sexes 
Figure 25 illustrates the decomposed parts of the two integrated data sets in all groups by age 
ranges (on the left, the phenomics joint part; on the right, the glycomics joint part). In general, the 
joint phenomics data set has lower signal/noise ratio, as compared with the joint glycomics data set; 
the latter also exhibits a higher percentage of joint part non-predicted by phenomics (thus predicted 
but something unknown but correlating with this part), when compared with the non-predicted by 
glycomics in the phenomics data set. These non-predicted parts become more evident as the sample 
size increases (range 20-85 years); this is especially true for the glycomics data set, in which the 
noise slightly decreases, in contrast to that in phenomics, which slightly heightens. 
In order to make results of joint loadings more comprehensive, the description that follows 
comprises the six groups (Ctrl F, Ctrl M, PreDiab F, PreDiab M, Diab F, Diab M) considering the 
full age range (20-85 years), instead of examining the groups in the four age ranges previously 
shown (Table 10). However, in the next section, the loading values for all age ranges will be 
presented. 
Table 10. Sample size of groups by age ranges and in the full age range and frequency of individuals in 
each age range per group 
Age Range Group 
Ctrl F Ctrl M PreDiab F PreDiab M Diab F Diab M 
20-44 y 37 (20.9%) 14 (13%) 18 (9.7%) 9 (7.4%) 2 (0.78%) 5 (1.7%) 
45-55 y 44 (24.9%) 39 (36.1%) 45 (24.3%) 28 (23.1%) 19 (7.4%) 32 (10.7%) 
56-70 y 74 (41.8%) 39 (36.1%) 88 (47.6%) 67 (55.4%) 157 (61%) 183 (61.4%) 
71-85 y 22 (12.4%) 16 (14.8%) 34 (18.3%) 17 (14%) 79 (30.7%) 78 (26.1%) 






Figure 26. Joint PC1 loading values of control males aged 20-85 y. 
Table 11. Top 10 joint PC1 loading values of phenomics and glycomics data sets in Ctrl M 
 
Phe_load Phenomics_var Gly_load Glycan_var 
1 -0.38972 Fibrinogen 0.519007 GP6 
2 -0.2994 TAFI 0.504762 GP3 
3 -0.28026 Neutrophils -0.4416 GP9 
4 -0.25263 White.Cells 0.426182 GP4 
5 -0.24958 CRP 0.219393 GP7 
6 -0.2493 HbA1c -0.19362 GP5 
7 -0.21139 Creatinine -0.07801 GP1 
8 0.202448 EGFR -0.06804 GP8 
9 -0.18609 Apo.B -0.04437 GP2 





Figure 27. Joint PC1 loading values of control females aged 20-85 y. 











Phe_load Phenomics_var Gly_load Glycan_var 
1 -0.41373 Age 0.54965 GP6 
2 -0.28302 Triglycerides -0.41975 GP2 
3 -0.27213 Alkaline.Phosphatase 0.36011 GP4 
4 -0.26922 WHR 0.352816 GP3 
5 -0.26905 Uric.Acid -0.34491 GP1 
6 -0.26828 Ferritin 0.292037 GP7 
7 -0.21569 CRP 0.196503 GP5 
8 0.198648 EGFR -0.11466 GP10 
9 -0.19739 Fibrinogen -0.07649 GP8 




Figure 28. Joint PC1 loading values of prediabetic males aged 20-85 y. 
 












Phe_load Phenomics_var Gly_load Glycan_var 
1 0.423193 TAFI 0.480792 GP8 
2 0.27211 Fibrinogen 0.430459 GP10 
3 0.268923 Platelets -0.42573 GP1 
4 0.251033 Transferrin -0.34782 GP7 
5 -0.24822 Age 0.330355 GP5 
6 -0.24152 RDW_CV -0.2525 GP4 
7 -0.22559 HDL -0.25155 GP2 
8 0.187685 Red.Cells -0.18286 GP3 
9 -0.18065 Ferritin -0.10071 GP6 




Figure 29. Joint PC1 loading values of prediabetic females aged 20-85 y. 
 
Table 14. Top 10 joint PC1 loading values of phenomics and glycomics data sets in PreDiab F 
 
Phe_load Phenomics_var Gly_load Glycan_var 
1 -0.35149 Age 0.525998 GP6 
2 -0.28861 Alkaline.Phosphatase 0.470829 GP4 
3 -0.26585 CRP 0.398601 GP3 
4 -0.26315 WHR -0.39574 GP2 
5 -0.23627 Fibrinogen 0.286845 GP7 
6 -0.22258 Triglycerides -0.17994 GP1 
7 0.212599 HDL -0.16396 GP10 
8 -0.20779 Uric.Acid -0.15836 GP9 
9 -0.20166 Azotemia -0.12574 GP8 





Figure 30. Joint PC1 loading values of diabetic males aged 20-85 y. 
Table 15. Top 10 joint PC1 loading values of phenomics and glycomics data sets in Diab M 
 
Phe_load Phenomics_var Gly_load Glycan_var 
1 -0.45435 Total.Protein 0.446021 GP8 
2 0.340855 CRP -0.42861 GP3 
3 0.33144 TAFI -0.40985 GP4 
4 -0.2797 Total.Iron 0.351605 GP10 
5 0.267464 WHR 0.274701 GP9 
6 0.236585 Fibrinogen -0.26355 GP1 
7 -0.22355 Total.Bilirubin 0.260263 GP5 
8 0.176752 Apo.B -0.21204 GP7 
9 0.156645 Cholesterol -0.18503 GP2 




Figure 31. Joint PC1 loading values of diabetic females aged 20-85 y. 
Table 16. Top 10 joint PC1 loading values of phenomics and glycomics data sets in Diab F 
 
Phe_load Phenomics_var Gly_load Glycan_var 
1 -0.3216 AST 0.479851 GP8 
2 -0.32025 Total.Protein -0.47455 GP3 
3 0.303065 TAFI -0.46463 GP4 
4 0.294732 HbA1c 0.432795 GP10 
5 -0.28893 Total.Iron -0.22885 GP7 
6 0.234337 CRP -0.20625 GP6 
7 0.211017 White.Cells 0.205671 GP5 
8 0.209755 Glycaemia -0.06177 GP1 
9 -0.20004 Total.Bilirubin -0.01761 GP9 
10 0.196148 Platelets -0.00388 GP2 
 
Figures 26-31 and Tables 11-16 show the loading variables in each joint set for each group. It can 
be noticed that three of the top 4 joint glycans in control males, control females and prediabetic 
females are GP6 (digalactosylated, fucosylated glycan, already described in the literature to be 
negatively associated with aging), GP3 and GP4 (monogalactosylated, fucosylated glycans), while 
GP2 (agalactosylated, bisecting GlcNAc, fucosylated, described too in the literature as typical of the 
aging phenotype) is also common in the top 4 in control females and prediabetic females (Figure 
27, Table 12). GP6, GP3 and GP4 are negatively correlated mainly with coagulation and blood 
67 
 
parameters in control males and with age (Figure 26, Table 11), alkaline phosphatase and lipid 
parameters in control females (Figure 27, Table 12). Conversely, the top 4 glycans in diabetic 
males and females are GP8, GP10, GP3 and GP4 (Figures 30-31, Tables 15-16). Prediabetic males 
also show GP8 and GP10 as top 2, and they are mainly positively correlated with three coagulation 
parameters (Figure 28, Table 13). In diabetics, both sexes show that GP8 and GP10 are positively 
correlated with diverse parameters from the phenomics data set, including lipid, coagulation, iron, 
blood parameters and factors used for the T2D diagnosis, while GP3 and GP4 are negatively 
correlated with those (Figures 30-31, Tables 15-16). 
When testing the correlation between phenomics and glycomics joint scores in each group (Table 
17), controls display joint PC1 correlations of the order of .7, prediabetics, of the order of .6, and 
diabetics of the order of .5. This observation highlights that the inter-variation phenomics/glycomics 
decreases with disease (from controls to prediabetics and to diabetics), thus that the intra-variation 
of each data set increases with disease, which, in turn, underlines the heterogeneity and/or 
complexity of disease and age. 
Table 17. Pearson intra-correlations between pairs of Phenomics/Glycomics joint scores 
Group Correlation between Phenomics/Glycomics joint scores 
Control males Joint PC1: R2=0.71 
Joint PC2: R2=0.61 
Control females Joint PC1: R2=0.70 
Joint PC2: R2=0.53 
Prediabetic males Joint PC1: R2=0.64 
Joint PC2: R2=0.59 
Prediabetic females Joint PC1: R2=0.64 
Joint PC2: R2=0.55 
Diabetic males Joint PC1: R2=0.53 
Joint PC2: R2=0.36 
Diabetic females Joint PC1: R2=0.52 
Joint PC2: R2=0.48 
 
23. Visualization of mean values and integrated weights  
 




Figure 33. Parallel plots of groups of variables (II) 
Figures 32 and 33 visually describes the differences among the groups of individuals in groups of 
variables – 42 phenotypical variables (excluding sex, age, telomere length) were grouped according 
to the tissue of production, their functionality or their diagnostic value: diagnostic parameters of 
T2D, lipid profile, liver, kidney, iron, coagulation, and cell counts & blood differential, and 
visualized with parallel plots for EDA –. N=1152, because individuals >85 years old had also been 
included. 
In T2D parameters, differences are clear, especially for glycaemia (fasting glucose) and HbA1c. In 
the remaining groups of variables, overall diabetics stand out over controls and prediabetics in 
WHR, LDL, Apo A1, triglycerides, GGT, ferritin and TAFI. There many variables that illustrate the 
heterogeneity of diabetics, by peaking up and falling down at the same time, especially for kidney, 
coagulation and blood parameters: EGFR, creatinine, azotemia, SDMA, ADMA, fibrinogen, TAFI, 
red cells, MCV, lymphocytes, eosinophils, monocytes. 
The next subsection shows in more detail the mean values per variable (on the left) as well as the 
loading values obtained with O2PLS (on the right) grouped by the same groups of variables as the 
parallel plots; only the most relevant variables within each group are shown. 
Diagnostic parameters of T2D 
 




Figure 35. Means and weights of glycated haemoglobin 
Fasting glucose and HbA1c. A clear segregation of groups is observed in the mean values plot. In 
addition, females present lower concentrations of fasting glucose across all age ranges than males, 
but higher concentrations of HbA1c (an indicator of long-term glucose), except at the age ranges 
20-44 and 45-55. Weights reach a maximum at 56-70 years (positive for all of them) and diminish 
again at 71-85 years, forming a triangle-like shape across the age ranges 45-55, 56-70, and 71-85. 
 
Figure 36. Means and weights of HOMA 
HOMA and fasting insulin. The means show that in the case of HOMA, groups are segregated, 
though at the age ranges 45-55 and 71-85, controls and prediabetics mix up. In the case of insulin, 
control and prediabetic females follow a similar curve to that of HOMA, that is at 45-55 years of 
age, they shrink, and at the next age range they raise again. Diabetic females present the highest 
concentrations of insulin in all age ranges (specially at 20-44y), except at 71-85 years of age. In 
males, prediabetics have higher levels of insulin in the first three age ranges, while diabetic males 
present constant concentrations across ages, and control males aged 20-44 years present the lowest 
levels. Weights do not follow any particular pattern, though in fasting insulin, groups tend to 








Figure 38. Means and weights of BMI 
 
Figure 39. Means and weights of WHR 
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BMI and WHR. Mean values show that diabetic females have the highest BMIs (29 to 32, according 
to the age range), while control females, the lowest (24 to 25), though at the age 56-70, it raises 
above 27. Diabetic males and prediabetic females and males present a BMI of 27-29 across all age 
ranges. With respect to WHR, males display much higher WHR than females in the three groups 
across all age ranges. Loading values do not follow a specific pattern. 
 
Figure 40. Means and weights of total cholesterol 
Cholesterol and LDL. Mean values illustrate that, in generall, females have more elevated 
cholesterol levels than males; in particular, diabetic males have the lowest concentrations of 
cholesterol and diabetic females, the highest in the age range 20-44 years old. In relation to LDL, 
diabetic males follow the same pattern as cholesterol levels across ages, and roughly the same 
applies in control and prediabetic females. Weights of the groups tend to converge at 56-70 years, 
while before and after they look more scattered. 
 




Figure 42. Means and weights of HDL 
HDL and Triglycerides. Mean values confirm that diabetic females aged 20-44 years have very low 
levels of HDL and, at the same time, very high levels of triglycerides as compared with males, 
while prediabetic and control females have the highest levels of HDL and the lowest levels of 
triglycerides. Weights in HDL in prediabetics and diabetics shrink at 56-70 years, while in controls 
they remain constant from 45-55 to 71-85 years; in triglycerides, prediabetics and diabetics have 
loading values clustered between 0 and -0.25, and controls of +0.25, in 56-70 years, the six groups 
group together to dissipate at 71-85 years. 
 
Figure 43. Means and weights of triglycerides 





Figure 44. Means and weights of alkaline phosphatase 
Alkaline phosphatase*. Overall, mean values show an upward trend across the four groups of age, 
with the exception of diabetic females, in which at 20-44 y, the mean value is exceptionally high, 
and conversely, very low in prediabetic females in the same group of age (*enzyme that comes 
primarily from the liver, but also from the bones; higher levels may indicate a problem in the liver 
or a bone disorder). Weights do not follow a specific pattern. 
 
Figure 45. Means and weights of total bilirubin 
Total bilirubin*. In this parameter, there is a general separation between males and females in the 
means, except at 45-55, in which values for control females raise and for diabetic males fall 
(*higher bilirubin levels indicate that either red cells are breaking down at an unusual rate or that 
liver isn’t breaking down waste properly and clearing it from blood). Loading values evolve at once 
for females with an inverted triangle-shaped pattern (fall at 45-55 y – raise at 56-70 y), while males 




Figure 46. Means and weights of AST 
AST*. In mean values, except for control males and diabetic females, there is a rise in ALT levels 
from 20-44 to 45-55 years, followed by a general stabilization across ages (*high levels may 
indicate hepatitis, cirrhosis, mononucleosis or other liver diseases). Weights do not follow a specific 
pattern. 
 
Figure 47. Means and weights of C reactive protein 
CRP*. Regarding mean values, except for diabetic females, who display very high levels of CRP at 
20-44, which slightly fall over ages, there is an upward trend in all groups from 20-44 years up to 
71-85 years (*it is a marker of inflammation, and high levels may indicate infection, cancer, 
cardiovascular disease, aging). Weights are similar for prediabetic males and females and diabetic 




Figure 48. Means and weights of creatinine 
Creatinine*. In mean values, there is a clear separation between males and females, the formers 
presenting higher mean values, and except for control/prediabetic males at 45-55 years of age, 
controls, prediabetics and diabetics are escalated in each sex (*high creatinine levels indicate that 
kidneys are not working properly). Weights follow a triangle-shaped pattern, except in control 
males and diabetic females, in which from 45-55 to 71-85 years they fall down. 
 
Figure 49. Means and weights of azotemia 
Azotemia*. Overall, mean values raise across age ranges, except in diabetic females (*high levels 
indicate abnormally high levels of nitrogen-containing compounds, such as urea, creatinine, waste 




Figure 50. Means and weights of uric acid 
Uric acid. Males means show higher levels of uric acid across all age ranges, and in the case of 
females, groups are escalated (diabetics presenting the highest and controls, the lowest). Loading 
values do not follow a specific pattern, though at 56-70 years, females aggregate. Weights do not 
follow a specific pattern. 
Iron biomarkers 
 
Figure 51. Means and weights of ferritin. 
Ferritin*. Males and females follow a diverse dynamics: diabetic males present higher mean values 
of ferritin that peak up at 45-55, followed by a reduction across ages; prediabetic and control males 
present their lowest levels at 45-55: females present the lowest levels at 20-44 years, which rise up 
until 56-70 years to diminish again at 71-85 (*it measures the amount of iron stored in the liver). 
Weights do not follow a particular pattern. Weights segregate negatively in prediabetics and 
diabetics and positively in controls at 45-55 years, at 56-70 years they cluster around 0 and minus 0, 





Figure 52. Means and weights of fibrinogen 
Fibrinogen. It clearly separates both groups and sexes, being males and controls the ones with 
lowest mean values. At 20-44 years, they are at their lowest levels and increase steadily until 71-85 
years, except for control females, who diminish fibrinogen concentrations at 71-85 years. Weights 
follow a triangle-shaped pattern (raise at 45-55 y – fall at 56-70 y), except in control and prediabetic 
females, that augment progressively from 20-44 y and 45-55, respectively. Weights follow roughly 
the same pattern than in CRP. 
 
Cell counts and blood differential 
 
Red cells. Mean values separate males and females, and the dynamics between sexes follows a 
different pattern: it diminishes across ages in males, while in females, red cells concentration starts 
raising at 45-55 years (except diabetics females at 20-44 years, who have high levels), and in 71-85 
years, that diminish in prediabetics and diabetics, while in female controls still increases. Weights 




Figure 53. Means and weights of haemoglobin 
Haemoglobin. Mean values clearly show much higher concentration of hemoglobin in males than 
females, and diabetic males show much higher levels at 20-44 years. Weights do not follow a 
specific pattern. 
 
Figure 54. Means and weights of white cells 
White cells. Diabetic males and females means are the highest, the latter group displaying a very 
high value at 20-44 years; prediabetic males and females have the same mean values, except a raise 
in males at 56-70, which are lower than diabetics, and control females present the lowest values. 





Figure 55. Means and weights of platelets 
Platelets. In this case, the sexes cluster, being females the group with higher mean values, which are 
at its highest at 20-44 years of age. Weights do not follow a specific pattern. 
 
Figure 56. Means and weights of telomere length 
Telomere length. Mean values vary according to the cohort (defined by age range, sex, and group), 
but it becomes evident that at 71-85 years diabetics present the lowest levels, followed by 





Figure 57. Means and weights of GP1 
GP1. Mean values increase over age and reach the maximum values at 71-85 years age; there are 
differences between sexes at 20-44 years, by which females show much lower values, though at the 
same time, they display a steeper raise until 45-55 years – for males, from the youngest age range 
until the 2nd age range, mean values remain roughly constant. Weights do not follow a specific 
pattern. 
 
Figure 58. Means and weights of GP2 
GP2. Mean values present a pronounced increase from younger ages until 56-70 or 71-85 years; in 
the case of diabetic males, diabetic females and control males (with this order) they present much 
higher mean values already at 20-44 years, in contrast to the other three groups, and start raising 
their values at 45-55 years. Weights do not follow a general pattern – they remain roughly constant 




Figure 59. Means and weights of GP3 
GP3. Means of GP3 depart from high positive values and fall down up until 56-70 years, except in 
diabetic males, and slightly raise again at 71-85 years. It is surprising that controls, prediabetics and 
diabetics are quite escalated, being controls generally the ones to have higher mean values. Weights 
separate males and females at 45-55 years (negative and positive loading values, respectively), 
converge at 56-70 years (female loadings become negative) to scatter again at 71-85 years. 
 
Figure 60. Means and weights of GP4 
GP4. Mean values follow a steep decrease from 20-44 years until 71-85 years for females, being 
controls the ones with higher values, followed by prediabetics, while in males do not decrease or 
decrease less from 20-44 years until 45-55 years, and increase/decrease or remain constant until 71-




Figure 61. Means and weights of GP5 
GP5. Mean values in control and prediabetic females are positive high at 20-44 years and sharply 
decrease until 45-55 years, while in diabetic females the contrary applies; from 45-55 to 71-85 years 
mean values slightly decrease, though the fall is more important in controls. Instead, males follow 
an approximate constant pattern from 20-44 until 71-85 years. Weights, except in control and 
diabetic males, present a triangle-shaped pattern (raise at 45-55 years – fall at 56-70 years), which is 
sharper in females. 
 
Figure 62. Means and weights of GP6 
GP6. Mean values are very high at 20-44 years for females, and they markedly decline, almost 
lineally, until 71-85 years old; in males, from 20-44 to 45-55 years remain constant for controls and 
diabetics while diminishing in prediabetics, and from 45-55 until 71-85 years they steadily lessen. 
Weights, except in prediabetic females, follow an inverted triangle-shaped pattern (fall at 45-55 





Figure 63. Means and weights of GP7 
GP7. Mean values are quite low for males at 20-44 years and steadily increase until 71-85 years; for 
females is quite the opposite, mean values are high at 20-44 years and diminish until 71-85 years, so 
that sexes mix. Weights follow a similar pattern to that of GP3. 
 
Figure 64. Means and weights of GP8 
GP8. Mean values show that groups are differentiated, that is females have higher values from 20-
45 years and keep roughly constant until 71-85 years, except for diabetic females at 20-44 years, 
which sharply rise until 45-55 years to diminish again. Weights follow a pattern from 45-55 to 56-
70 years, in which males have high positive values from 20-44 years until 45-55 years, while 
females exhibit less positive, neutral or negative loadings at 45-55 years, and increase until 45-55 




Figure 65. Means and weights of GP9 
GP9. Mean values are lower for females than males across ages, except control males, which 
present a lower loading value at 20-44 years than the rest of the groups, and diabetic females have a 
much higher value than the other groups; from 45-55 years, means increase until 56-70 or 71-85 
years. Weights are positive from 45-55 years in males and negative in females, though in males they 
steeply decrease from 56-70 years, while the decrease in females is less important. 
 
Figure 66. Means and weights of GP10 












The general aim of this study was: 
• To identify the major sources of Phenomics variation (when integrated with N-glycans) by 
integrating endophenotypes/groups of biological variables, composed by biologically 
similar variables, that is variables diagnostic of T2D, lipid profile, liver biomarkers, kidney 
biomarkers, iron and coagulation parameters and blood factors, again in the six groups of 
individuals in four age ranges and the full age range, and to identify N-glycans changes 
according to these endophenotypes and to the group. 
The specific aim of this study was: 
• To follow the procedure described in the 2n objective of the aims in Part I, but in addition 
to integrate phenomics with glycomics, to apply O2PLS in seven additional sets of 
endophenotypes with N-glycans. Unlike in Part I, for the integration Phenomics/Glycomics, 






















24. Sources of variation in Phenomics, T2D, Lipids, Liver, Kidney, Iron, 
Coagulation, Blood & Glycomics data sets 
 
Figure 67. Decomposed parts of the O2PLS integrations between 8 different data sets and 10 N-glycans in 
four different age ranges and the total age range by groups and sexes 
Figure 67 illustrates the decomposed parts of the eight integrated data sets with N-glycans in all 
groups by age ranges (“T2D” refers to the four variables used for diagnosing or quantifying T2D, that is 
fasting glucose, fasting insulin, HbA1c and HOMA). In general, the joint parts of the endophenotypes 
sets have higher signal/noise ratio, as compared with the joint phenomics data set. Conversely, in 
the glycomics joint part, while the covariating Phenomics exhibits a high signal/noise ratio, the 
covariating endophenotypes show a much lower signal/noise ratio. The same applies to the non-
predictive parts, which are in higher percentage in joint endophenotypes parts but in lower 
percentage in the joint phenomics part, when compared with the non-predicted by glycomics in the 
phenomics data set. Instead, in the glycomics joint part, the covariating phenomics set presents a 
high percentage of non-predicted by phenomics part, while this percentage falls down in the 
glycomics joint of the covariating endophenotypes. 
In order to make results of joint loadings more comprehensive, the description that follows 
comprises the six groups (Ctrl F, Ctrl M, PreDiab F, PreDiab M, Diab F, Diab M) considering the 
full age range (20-85 years) in each of the 8 integrated data sets, instead of examining the groups in 
the four age ranges previously shown.  
The intra-correlations between pairs of joint PC scores show that in prediabetics, in both sexes, N-
glycans scores correlate less with T2D diagnostic parameters and lipid profile scores, while they 
display a high correlation with liver and coagulation scores (Table 18). Conversely, in diabetics, in 
both sexes, the correlation of joint scores between N-glycans and T2D diagnostic parameters and 
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lipid profile is surprisingly low. In turn, the correlation with liver and coagulation is higher, yet 
much lower than the same correlations observed in prediabetics, which may be explained by 
medication (Table 7). By contrast, in comparison to controls and prediabetics, the correlation of the 
glycomics scores with kidney scores increases (Table 18). Yet, the expected tri-/tetragalactosylated 
glycans GP8 and GP10 are not in the top 4 of glycomics loadings integrated with liver, except for 
diabetic females, though they are in the coagulation data set in prediabetic males, diabetic females, 
and diabetic males. Instead, the top 3 N-glycans common in both prediabetic males and females are 
GP6 (digalactosylated, fucosylated), GP3 (monogalactosylated, fucosylated) and GP4 
(monogalactosylated, fucosylated) (Table 19). Regarding controls, the highest intra-correlations 
between joint PCs are found in T2D, lipids, kidney and blood data sets pairing with N-glycans, and 
iron and coagulation for males too (Table 18). 
Table 18. Pearson intra-correlations of the joint PC scores in each pair of integrated data sets 
Group Phenomics/Gly T2D/Gly Lipids/Gly Liver/Gly Kidney/Gly Iron/Gly Coagulation/Gly Blood/Gly 



























































































































































































In this line, the inter-correlations among joint PC scores, for control males and females are mid-
low: in males, the highest correlations after the phenomics/glycomics joint parts are 1) between the 
glycomics joint PC1 integrated with T2D and the coagulation joint PC1 (R2=-0.46), and 2) between 
the blood joint PC1 with its glycomics joint PC1 counterpart (R2=0.41) (Figure 68); while in 
females, the highest correlations after the phenomics/glycomics joint parts are 1) the glycomics 
joint PC1 [integrated with T2D] and lipids joint PC1 (R2=0.5) and 2) T2D joint PC1 with lipids 
joint PC1 (R2=0.45) and the glycomics joint PC1 [integrated with liver] with the glycomics joint 
PC2 [integrated with liver] (R2=0.45) (Figure 69). Interestingly, in prediabetics and diabetics 
(Figure 70-73), there can be observed very high inter-correlations: the glycomics joint PC1 scores 
[integrated with phenomics] are strongly associated with glycomics joint PC1 [integrated with T2D] 
(R2=0.96 PreDiab M, R2=0.99 PreDiab F, R2=0.7 Diab M, R2=-0.82 Diab F), glycomics joint PC1 
[integrated with lipids] (R2=0.83 PreDiab M, R2=0.99 PreDiab F, R2=0.92 Diab M, R2=0.9 Diab F), 
glycomics joint PC1 [integrated with liver] (R2=-0.14 PreDiab M, R2=-0.98 PreDiab F, R2=0.98 
Diab M, R2=0.92 Diab F), glycomics joint PC1 [integrated with kidney] (R2=-0.89 PreDiab M, 
R2=0.95 PreDiab F, R2=0.95 Diab M, R2=0.78 Diab F), glycomics joint PC1 [integrated with iron] 
(R2=0.88 PreDiab M, R2=-0.1 PreDiab F, R2=0.2 Diab M, R2=-0.97 Diab F), glycomics joint PC1 
[integrated with coagulation] (R2=-0.80 PreDiab M, R2=0.99 PreDiab F, R2=-0.96 Diab M, R2=-
0.93 Diab F), and with glycomics joint PC1 [integrated with blood] (R2=0.89 PreDiab M, R2=0.79 
PreDiab F, R2=-0.84 Diab M, R2=0.12 Diab M). These observations highlight that N-glycans are 
not specific for the endophenotypes but rather indicative of a biological condition. On the other 
hand, the highest inter-correlation of phenomics joint PC1 is with liver joint PC1 for prediabetic 
females (R2=-0.74), diabetic males (R2=0.67) and diabetic females (R2=0.69), while for prediabetic 
males, the highest is with glycomics joint PC1 [integrated with blood] (R2=0.64). This indicates that 
liver is one of the primarily organs to be affected in T2D disease. 
It is to note the inter-correlations that are equal 0; they are attributed to an intrinsic assumption of 
O2PLS, thereby the reciprocal joint is uncorrelated with the following joint PC (for example, the 
glycomics joint PC1 [integrated with phenomics] has a correlation of 0 with phenomics joint PC2). 
 




Figure 69. Pearson inter-correlations among the joint PCs in Ctrl F 
  
 




Figure 71. Pearson inter-correlations among the joint PCs in PreDiab F 
 




Figure 73. Pearson inter-correlations among the joint PCs in Diab F 
Intra- and inter-correlations between pairs of joint PCs and individual joint PCs, respectively, 
therefore, point to one underlying condition having a functional impact in multiple organs and 
tissues, rather than different medical entities, in prediabetics and diabetics. Table 19 reinforces this 
hypothesis, as the most common N-glycans covariating with the endophenotypes sets are GP3, GP4, 
GP6 for PreDiab F, GP5, GP8, GP10, GP1, GP7 for PreDiab M, GP3, GP4, GP8, GP10 for Diab F, 
and GP3, GP4, GP7, GP8, GP10 for Diab M; all of them fairly constant across glycomics scores of 
the same group, thus confirming the inter-correlations results.  
 
Table 19. Top 4 loading values of the joint parts for each pair of integrated data sets 
Group Phenomics/Gly T2D/Gly Lipids/Gly Liver/Gly Kidney/Gly Iron/Gly Coagulation/Gly Blood/Gly 
































































































































































































































































































































































































































































































N-glycans species change in conditions of inflammation and metaflammation. In the frame of T2D 
and metabolic syndrome, it is not clear whether these alterations in N-glycans profile are the cause 
or the consequence of the disease. The clinical diagnostic of T2D is achieved through the criteria 
established by ADA (2020); however, it has two potential drawbacks: it takes an average of 7 years, 
and, when T2D is confirmed, the individual already presents an overt clinical symptomatology that 
rarely ameliorates and, instead, it progresses towards vascular complications. Thus, when the 
clinical diagnostic of T2D is achieved, the quality of life of an individual and the lifespan will likely 
have already been conditioned. As a whole, the increasing number of geriatric population, along 
with the late diagnosis of T2D, will lead to a socio-economical burden is going to be difficult to 
manage, unless systematic changes in the health system are carried out and/or more biomarkers of 
T2D/dysmetabolism/aging (which often go hand in hand) are found.  
Here, we firstly address whether N-glycans could predict better the diabetic or non-diabetic status 
than HbA1c, used in clinical routine as parameter to diagnose T2D (ADA, 2020). Results confirmed 
that HbA1c is better for the diagnosis than N-glycans (AUCHbA1c = 0.97, AUCN-glycans = 0.71). 
Thereupon, we aimed to integrate 44 clinical variables of different sources (including T2D 
diagnostic parameters, biochemical parameters from the lipid profile, liver, kidney, and cell counts 
and blood differential factors) with 10 N-glycans obtained with DSA-FACE in six groups of 
individuals, that is, control males, control females, prediabetic males, prediabetic females, diabetic 
males, and diabetic females, in four age ranges, that is, 20-44, 45-55, 56-70, 71-85 years of age, and 
the full age range. We made these subgroups for different reasons: i) males and females present a 
different biology, ii) clinical parameters and N-glycans change with age, and iii) controls, with age, 
tend to resemble prediabetics/diabetics, especially from 60 years on, since as healthy individuals get 
older tend to become less healthy and start presenting subclinical alterations. Results of the six 
groups, focusing on the full age range, evidenced from the loading values of the integrated 
variables, in hand with their corresponding mean values, that N-glycans GP3, GP4, GP6 are 
negatively associated with age in the six groups, while GP8 and GP10 are positively associated with 
diverse clinical parameters, especially from coagulation and lipidic profile, in diabetic males and 
females, and in prediabetic males. These signals are suggestive of being some of the team players 
mirroring a metabolic dysfunction. In addition, the decreasing intra-correlations between joint 
phenomics and joint glycomics from controls to diabetics supports the heterogeneity and/or 
complexity of T2D and/or metabolic syndrome.  
To the best of our knowledge, there are currently no previous studies integrating clinical variables 
and N-glycans in the context of metaflammation and T2D. Notwithstanding, we confirmed GP6 
(digalactosylated, fucosylated) as an N-glycan that negatively correlates with aging (Vanhooren et 
al., 2008; 2010; Kristic et al., 2014), and GP8 and GP10 (multi-branched, galactosylated N-glycans) 
as N-glycans associated with lipidic profile and T2D diagnostic parameters (Testa et al., 2015, 
Keser et al., 2017). 
We further aimed to better understand whether these N-glycans changes arise from a common 
medical condition or there are specific signatures of N-glycans according to the endophenotypes to 
which they are integrated. Results of the intra-correlations between pairs of joint PCs scores showed 
that, in prediabetics, N-glycans scores correlate less with T2D diagnostic parameters and lipid 
profile scores, while they displayed a high correlation with liver and coagulation scores. 
Conversely, in diabetics the correlation of joint scores between N-glycans and T2D diagnostic 
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parameters and lipid profile was surprisingly low; in turn, the correlation with liver and coagulation 
was higher, yet much lower than the same correlations observed in prediabetics. Overall, this could 
be indicative of the fact that medication changes N-glycan profile, as diabetics take more drugs than 
prediabetics (and controls) (Table 7), especially for lowering the glycaemic and lipid indexes, or 
anti-aggregants for vascular disease-related conditions. On the other side, the highest intra-
correlation in controls was found in the T2D set, which may be attributed to the fact that these 
control individuals are not the prototype of healthy controls, as the mean BMI is 28.32 for males 
and 25.75 for females, and thus it is suggestive of an onset of biological dysregulation. Secondly, 
inter-correlations between individual joint PCs scores show that in prediabetics and diabetics N-
glycans are generally the same when integrated with different endophenotypes, instead of revealing 
a specific signature for each endophenotype, suggesting one biomedical condition; whereas in 
controls, inter-correlations are too low for interpretation.  
Together, this extensive characterization of the phenotype by integrating clinical and N-glycans 
data has shed light into the subclinical window of T2D/metabolic syndrome, obtained from healthy 
younger controls and less healthy older controls and prediabetics, and into the clinical window, 
obtained from younger and older diabetic patients. Overall, individuals should not only be studied 
on the basis of T2D diagnostic parameters, but also considering a combination of parameters 
characteristic of insulin resistance (metabolic) syndrome, which starts before the clinical onset and 
diagnosis of T2D, thus in control and prediabetic individuals. Further research is needed to refine 
and elaborate this design. Here we identify several future directions that can build on our work for 
investigating the joint variation between clinical and glycomic variables or other metabolites that 
provide further insight into the pathology.  
First, our analysis was limited to a single cohort, and one that lacked ethnic minority populations. 
Replication in other cohorts is needed, and replication using a larger number of younger and older 
healthy controls, younger and older less healthy controls, prediabetics and diabetics can also 
provide additional perspectives. Larger samples can also help understanding the less common 
phenotypes.  
Second, DSA-FACE N-glycans are low-dimensional and have the disadvantage that sialic acids are 
cut-off from the sugar, which blurs the interpretation of results. Further studies are needed that use 
N-glycans obtained with other technologies which include sialic acids and produce more N-glycan 
species, and not only from whole plasma glycome, but also from IgG glycome, which is especially 
relevant for understanding the role of inflamm-aging and metaflammation played by N-glycans. 
Third, the nature of the cross-sectional study hinders the ability to answer the question “do N-
glycans and other biochemical parameters change over the course of preclinical (that is, insulin 
resistance and impaired insulin secretion) to clinical diagnoses (obesity and/or T2D, T2D 
complications, metabolic syndrome)?” 
Our findings suggest that future studies of T2D/dysmetabolism incorporate longitudinal repeated 
measures of biomarkers to track change. They also suggest that these investigations of 
T2D/dysmetabolism incorporate multiple biomarkers to track change across different organ 
systems.  
Within the bounds of these limitations, the implication of the present work is that it is possible to 




CHAPTER 2: Estimation Of An Innovative Composite Aging Clock  
As Biomarker For Type 2 Diabetes And Related Metabolic 
Phenotypes 
11. INTRODUCTION 
Aging is a time-dependent multifactorial process that results in a global deterioration of the 
physiological functions and elevated risk of pathologies, including cardiovascular disorders, 
neurodegenerative diseases, cancer and diabetes (López-Otín et al., 2013). It is well-known that age 
is a major risk factor for functional impairments, chronic diseases and mortality; however, the aging 
rate is not universal for humans, as it depends on the individual exposure/resilience trade-off. 
Consequently, chronological age may not be a reliable indicator of the body’s physiological decline, 
but rather a proxy of the aging growth rate. In this line, the unprecedented growth rate of world’s 
aging population is highlighting the need for better understanding the aging process and the 
determinants of healthy and unhealthy aging. 
Traditionally, the aging rate has been estimated through the mortality curves of populations, i.e. 
individuals are tracked until their death to estimate their “biological age” at time points when they 
were alive (Moskalev, 2020). Thus, to measure the functional decline, and to predict the morbidity 
onset and the life expectancy with this method are not possible.  
An alternative to mortality risk estimation for measuring the biological age is the identification of a 
set of endophenotypes that change with aging, called “biomarkers of age”, that best predict 
chronological age. This is where the “paradox of biomarkers”, reformulated by Hochschild (1994), 
comes into play: “A hypothetical biomarker that approaches perfect correlation with chronological 
age could be replaced by chronological age and would be insensitive to differences in aging among 
individuals.” The core of the paradox is that biological age is estimated by multiple linear 
regression, which uses chronological age as dependent variable and a set of biological predictors as 
independent variables, thus resulting in biological age equal to chronological age (Klemera and 
Doubal, 2006). 
According to the American Federation for Aging Research (AFAR), a biomarker of age has to fulfil 
the following criteria (Johnson, 2006):  
1. it must predict the rate of aging (it should tell exactly where a person is in their total 
lifespan and it must be a better predictor of lifespan than chronological age); 
2. it must monitor a basic process that underlies the aging process, not the effects of disease; 
3. it must be able to be tested repeatedly without harming the person (for example a blood test 
or an imaging technique); 
4. it must be something that works in humans and in laboratory animals, such as mice (so that 
it can be tested in laboratory animals before being validated in humans). 
However, the existence of biomarkers meeting all AFAR criteria has been called into question, as 
organs and tissues age at different rates (Franceschi et al., 2018), which makes the estimation of the 
overall individual aging rate difficult and, in turn, the estimation of the overall population aging 
rates, too. Examples of aging rate types between individuals are: persons with Down syndrome (a 
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progeroid syndrome), who show accelerated aging from a young age; individuals with T2D (an age-
related disease), who have an increased risk for CVD, which make them more likely to age at faster 
rates than matched individuals without T2D; aged individuals with history of disease; aged 
individuals with no history of disease; and centenarians, who have avoided or postponed age-related 
diseases in their 60s, 70s and 80s and show decelerated aging. Thus, the phenotype in the elderly 
depends on the genetic background and the interaction with environment and lifestyle. 
Further impediments to identify biomarkers of aging are the challenge to disentangle the intrinsic 
processes underlying healthy aging from the ones of unhealthy aging or of onset of age-related 
diseases and to capture independent and overlapping mechanistic processes driving the aging 
process. To date, the biological mechanisms underlying aging that have been proposed are the 
“hallmarks of aging” (López-Otín et al., 2013) and the “seven pillars of aging” (Kennedy et al., 
2014). 
Many research studies have described biomarkers of aging, which constitute tiny pieces 
encompassing the complex puzzle of the aging process. These can be molecular – DNA 
methylation, transcriptome-based, proteome-based, metabolome-based, N-glycans, telomere length 
– and phenotypical – blood measures, neuroimaging, frailty, muskoskeletal functions –.  
25. Molecular biomarkers of aging 
27. DNA methylation 
A promising biomarker of age is DNA methylation age (DNAm), also referred as epigenetic clock, 
because it applies to all sources of DNA (cells, tissues and organs) and to the whole age spectrum 
(from prenatal tissue to tissues of centenarians) (Horvath and Raj, 2018).  
So far, at least nine robust state-of-the-art estimators have been described: seven epigenetic clocks 
based on DNAm (Horvath, 2013; Horvath et al., 2018; Hannum et al., 2013), Weidner et al., 2014, 
Levine et al., 2018; Lu et al., 2019), and CpG sites (genes islands ELOVL2 and FHL2, Garagnani et 
al., 2012).  
Horvath and Hannum epigenetic clocks show high correlations with chronological age (r=0.96 for 
Horvath and r=0.91 for Hannum) and small, mean absolute deviations (MAD) from calendar age 
(3.6 and 4.9 years, respectively) in their corresponding validation cohorts. Weidner reported a 
MAD=3.34 years and R2=0.98 in the discovery cohort, and a MAD of 5.79, 5.52 and 4.02 years in 
the validation cohorts. Sample size for the three algorithms was of N=8000 for Horvath, N=656 for 
Hannum and N=151 for Weidner. The Horvath clock is a multi-tissue predictor based on 
methylation levels of 353 CpG sites on the Illumina 27k array, Hannum clock uses only 71 CpG 
sites from the Illumina 450k array and performs best using whole blood samples, and Weidner 
identifies 3 age-related CpGs by using bisulfite pyrosequencing (Horvath, 2013; Hannum et al., 
2013; Weidner et al., 2014; Jylhävä et al., 2017). Selection of CpG sites was done using elastic net, 
a penalized regression multivariate model, in Horvath and Hannum (yet, they only have 6 CpG sites 
in common), and a recursive feature elimination in Weidner. The most important characteristics 
about Horvath and Hannum clocks is their ability to predict all-cause mortality independent of 
classic risk factors (Chen et al., 2016). When it comes to aging phenotypes, Marioni and colleagues 
reported that age and sex-adjusted Horvath’s clock was associated with different measures of 
fitness, that is, epigenetic age acceleration was associated to a poorer cognitive performance, lower 
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grip strength, and poorer lung function at baseline (Marioni et al., 2015), though the baseline 
DNAm at 70 years did not predict the rate of change of these fitness measures. Other associations 
have been performed in blood, in which the Horvath and Hannum clocks correlate with certain 
blood cell types that also show age-related changes (Marioni et al., 2015; Chen et al., 2016). The 
fourth clock, Levine’s clock, named DNAm PhenoAge, represents an improvement of the previous 
epigenetic biomarkers for several reasons: i) 41/513 CpGs in DNAm PhenoAge were shared with 
the Horvath clock, 5 of which were also shared with the Hannum’s clock), ii) unlike the previous 
epigenetic clocks, which aimed to optimize the correlation of the CpGs predictors with 
chronological age, the CpGs in DNAm PhenoAge were tuned to predict a multi-system proxy of 
physiological dysregulation (phenotypic age). As a result, the CpGs with the highest effect sizes in 
the new clock did not correlate with chronological age, but instead were related to the difference 
between phenotypic and chronological age (i.e. divergence in the rate of aging).  
Several investigations have also analysed the association between the epigenetic age and diseases of 
aging: in Alzheimer’s disease (AD) patients, prefrontal cortex was associated with the presence of 
plaques, amyloid load and a decline in global cognitive functioning, episodic memory and working 
memory (Levine et al., 2015); in Parkinson’s disease (PD), DNAm is higher for PD patients when 
compared with controls, after adjusting for cell blood composition (Horvath and Ritz, 2015); in 
cancer, the Hannum clock presents increased epigenetic age in the tested tumor tissues (Hannum et 
al., 2013), whereas the Horvath’s clock shows increased DNAm only in certain cancer types 
(Horvath, 2013; Horvath, 2015); in osteoarthritis, the Horvath’s clock was associated with an 
increased DNAm in the joint of the affected cartilage, but not in the nearby bone or blood (Vidal-
Bralo et al., 2016). 
The two CpG sites considered epigenetic markers map in the gene islands of ELOVL2 and FHL2. 
Both CpG sites display high correlations with chronological age (r=0.92 for ELOVL2 and r=0.80 for 
FHL2) that correspond to a progressive increase in methylation with age. The discovery was made 
on 64 subjects with Illumina 450k array on whole blood DNA and validated with a cohort of 501 
subjects analysed with Sequenom’s EpiTYPER (Garagnani et al., 2012). A subsequent investigation 
examined the relationship between DNA methylation and the prospective development of breast 
cancer and colorectal cancer in 845 subjects (Durso et al., 2017). The authors found that the two 
most used epigenetic clocks (Horvath and Hannum) were unable to detect age acceleration effects 
in females blood that were later diagnosed of breast cancer, while ELOVL2 did; conversely, 
Horvath’s clock and FHL2 predictor were associated with colorectal cancer in males (Durso et al., 
2017). 
28. Transcriptomics-based 
Ferrucci and colleagues conducted a transcriptome-wide gene expression analysis in peripheral 
blood leukocyte samples of individuals aged 30-104 years (N=698), to determine which transcripts 
were most associated with advancing age in the InCHIANTI study (Ferrucci et al., 2000), and they 
found that using expression levels of only 6 genes (LRRN3, CD27, GRAP, CCR6, VAMP5 and 
CD248), they were able to distinguish between younger (age<65) and older subjects (age≥75) with 
high accuracy (Ferrucci et al., 2000). Later on, they studied the performance of a modified model in 
three populations and determined whether individuals predicted to be biologically younger than 
their chronological age had biochemical and functional measures consistent with a younger 
biological age: individuals with younger gene expression patterns had higher muscle strength and 
serum albumin, and lower interleukin (IL)-6 and blood urea concentrations relative to “biologically 
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older” individuals (OR=1.05, 1.13, 0.61, 0.98; p=3.2×10−2, 2.7×10−4, 1.1×10−2, 2.6×10−2 
respectively) (Holly et al., 2013).  
Another large study performed a whole-blood gene expression meta-analysis in 14,983 individuals 
and identified 1,497 genes that were differentially expressed with chronological age; from these 
significant genes, the age-associated ones were enriched for the presence of potentially functional 
CpG methylation sites in enhancer and insulator regions. The authors calculated the “transcriptomic 
age” from the gene expression profiles and showed that differences between transcriptomic age and 
chronological age were associated with processes characteristics of aging, such as blood pressure, 
cholesterol levels, fasting glucose, and BMI (Peters et al., 2015).  
In another study, Fleischer and colleagues generated a data set of genome-wide RNA-seq profiles of 
human dermal fibroblasts from people aged 1 to 94 years old to test whether signatures of aging are 
encoded within the transcriptome (Fleischer et al., 2018). With this purpose, they made use of an 
ensamble machine learning method that predicts age to a median error of 4 years, thus 
outperforming algorithms proposed by prior studies that predicted age from DNA methylation 
(Horvath, 2013; Hannum et al., 2013; Peters et al., 2015; Xu et al., 2015). 
A further investigation aimed to account for the inter-individual variability by performing gene 
expression analysis in T lymphocytes from 27 healthy monozygotic twins aged between 22 and 98 
years (Remondini et al., 2017). The authors obtained a transcriptomic signature of 125 genes, from 
which chronological age could be estimated. It should be noted the relevance of this work as this 
signature represents genes involved in normative aging, which expression changes independently of 
environmental factors. 
29. Proteome-based 
A recent study quantified 2,925 plasma proteins from 4,263 individuals of 18 to 95 years old and 
developed a new bioinformatics approach that uncovered marked waves of changes in the proteome 
in the 4th, 7th and 8th decades of life (Lehallier et al., 2019). Specifically, to determine whether the 
plasma proteome could predict biological age and serve as a “proteomic clock”, the authors used 
2,817 randomly selected subjects to fine-tune a predictive model that was tested on the remaining 
1,446 subjects. Indeed, they identified a sex-independent plasma proteomic clock consisting of 373 
proteins, thereby individuals who were predicted to be younger than their chronological age 
performed better on cognitive and physical tests. The work is promising, because the panel of 373 
proteins can be used to assess the relative health of an individual and to measure health span, and 
thus, despite it needs more large-scale validation, it can be considered analogous to epigenetic 
clocks based on DNA methylation patterns (Lehallier et al., 2019). 
A subsequent research, by Johnson and colleagues, systematically reviewed 36 different proteomics 
studies of proteomics that significantly changed with age (Johnson et al., 2020). They discovered 
1,128 proteins that had been reported by ≥2 or more analyses and 32 proteins that had been reported 
by ≥5 analyses, and proposed two proteomic aging clocks, a smaller panel and a larger panel 
comprised of proteins that were reported to change with age in plasma in ≥4 and ≥3 studies, 
respectively (Johnson et al., 2020). They achieved so by validating the plasma proteins with an 
online aging plasma proteome interface created by Lehallier and colleagues and by demonstrating 
that these protein panels are bona fide aging clocks that can accurately predict patient age in a large 
cohort of 3,301 individuals. The authors reported that 2/3 of 1,128 proteins changed with age in ≥2 
tissues/cell types, by which they suggested that, similar to the Horvath’s clock, a single proteomic 
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clock might be estimated with the use of machine learning algorithms in a multi-tissue human 
dataset (Johnson et al., 2020).  
30. Metabolome-based 
The clinical manifestations of many age-related diseases, such as T2D, AD, PD are well known. 
However, the complex interconnection of biomolecular pathways contributing to the aging process 
are just beginning to be unveiled. In other words, the few pathways described so far, such as DNA 
damage or accumulation of ROS, have been seen as independent processes, but most of the links 
among them are missing – one exception is the evidenced interconnection between DNA damage 
and metabolic control (Bai et al., 2011; Sahin et al., 2011). Examples of metabolic systems known 
to be implicated in aging are the insulin/IGF1 pathway, the mTOR, sirtuin and AMP-activated 
protein kinase (AMPK) pathways (Houtkooper et al., 2011). 
Several studies have aimed to identify metabolic signatures of aging. A key investigation that shed 
light on the functioning of metabolic processes in longevity combined 1H-NMR profiling and 
targeted mass spectrometry (MS) approaches in a human aging cohort comprised mostly of female 
centenarians, elderly, and young individuals, and showed that, with increasing age, targeted MS 
profiling of blood serum markedly decreases in tryptophan concentration, while an unique alteration 
of specific glycerophospholipids and sphingolipids are seen in the longevity phenotype (Collino et 
al., 2013). The authors proposed that the overall lipidome changes reflect the centenarians unique 
capacity to adapt to the accumulative oxidative and chronic inflammatory conditions of their 
extreme aging phenotype. Yet, the observational nature of the study made unable to establish causal 
links between the inflammatory status, aging, and modulation of lipid metabolism (Collino et al., 
2013).  
In this line, as in other omics studies, the lack of multilevel integration of different data sets hinders 
the understanding of the metabolic decline during aging that predisposes to age-related diseases. A 
novel work systemically integrated in vivo phenotyping with gene expression, biochemical analysis 
and metabolomics in young and 2 year old mice. They analysed muscle and liver affected pathways, 
and found that alterations in glucose and fatty acid metabolism and redox homeostasis translated in 
decreased long chain acylcarnitines and increased fatty acid levels and a marked reduction in 
various amino acids in the plasma of aged mice. The authors concluded that such metabolites serve 
as biomarkers for aging and health span (Houtkooper et al., 2011). 
31. Glycomics 
As mentioned before, glycans are product of a complex pathway that involves hundreds of different 
proteins and are encoded in a complex dynamic network of hundreds of genes (Lauc and Zoldoš, 
2010). Unlike the genome, which remains constant in life, glycans are stable molecules that change 
with physiological and pathological conditions; thus, their relative quantification and analysis can 
contribute to the understanding of the underpinning processes of aging. 
A pioneering study conducted by Krištić and colleagues confirmed that glycans, indeed, are a novel 
biomarker of chronological and biological ages (Krištić et al., 2014). The authors analysed 24 
immunoglobulin (Ig)G plasma N-glycans using the UPLC technology in N=906 subjects from Vis 
island, N=915 subjects from Korčula island, N=2035 subjects from Orkney islands, and N=1261 
subjects from TwinsUK cohort. The researchers built a predictive model of age, termed 
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“GlycanAge”, by which 3 IgG N-glycans, FA2B, FA2G2, and FA2BG2, explaining 58% of 
variance, were found to be markers of age (Krištić et al., 2014). Equally important was the work 
performed by Vanhooren et al. (2008; 2010) with the use of the DSA-FACE technology in total 
blood serum, in which they described that the GlycoAge Test, obtained from the log ratio of P1/P6, 
is better than chronological age at estimating physiological age, and is higher in dementia and 
Cockayne syndrome than in healthy individuals.  
It is worthy to note that, as Levine et al. (2018) highlighted, the biological age should not be 
estimated by optimizing the correlation of the predictors with chronological age, and instead it 
should focus on time-dependent weights of these predictors. In this line, Krištić et al. (2014), 
similar to Levine and colleagues with DNAm PhenoAge, defined the GlycanAge = intercept + 
β1·GP6 – β2·GP62 – β3·GP14 + β4·GP15, separately in males and females, but estimated the 
difference in the biological age with chronological age by computing the delta median of the 
GlycanAge calculated both in 2003 and in 2013 in the same subjects – in the case of females 
(N=20, aged 38-50) the median delta GlycanAge was of 9.6 years, while for the males (N=6, aged 
43-49) was equal to 0.6.  
26. Phenotypical biomarkers of aging 
32. Composite-based 
Other investigations have searched for multiple biomarkers that combined produce a single 
biological age predictor, which can be advantageous in biological research, public health and 
clinical practice. 
An important study was conducted by Levine et al. (2013), in which he compared the predictive 
ability of 5 different statistical methods for estimating Biological Age using the cohort National 
Health and Nutrition Examination Survey III (NHANES III). The study comprised N=9,389 
subjects, aged 30-75 years, that within 18-year follow-up, 1,843 deaths were recorded. Results 
showed that the Klemera and Doubal method (KDM) (Klemera and Doubal, 2006) was the most 
reliable predictor of mortality and performed significantly better than chronological age; thus, it 
may represent a useful algorithm for future research studies (Levine, 2013). In this line, other 
research works have also employed this algorithm to estimate BA (Belsky et al., 2015).  
Belsky and colleagues used a dual approach to study Biological Age and the Pace of Aging in 
N=954 young adults from the Dunedin Study birth cohort. Biological Age was obtained cross-
sectionally using the KDM, while the Pace of Aging was measured longitudinally at 3 different 
points of time. Results evidenced that study members with older Biological Age had faster Pace of 
Aging over the preceding 12 years (Belsky et al., 2015). Authors suggested as strategy for future 
studies to use longitudinal repeated measures of biomarkers to track change of multiple tissues and 
organs, and that these studies will require new statistical methods to measure the Pace of Aging, 
likewise KDM currently calculates Biological Age. 
A totally different approach was used by Sebastiani and colleagues, thereby they measured 19 blood 
biomarkers, comprised of hematological measures, lipids profile, and markers of inflammation and 
frailty in 4,704 participants of the Long Life Family Study (LLFS), aged 30-110 years. Briefly, they 
used an agglomerative algorithm to group LLFS subjects into clusters, which yielded 26 biomarker 
signatures, and they subsequently correlated them with longitudinal changes in physiological 
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functions and incident risk of cancer, CVD, T2D, and mortality, with the end goal of testing 
whether these signatures were associated with differences in biological aging. One of those 
signatures was associated with lower mortality, morbidity and more healthier aging, while nine 
other signatures were associated with higher risks for mortality, morbidity and less successful 
aging. Seven of the signatures were replicated in an independent cohort (Sebastiani et al., 2017). 
To conclude with the overview of the current described molecular and phenotypical clocks, future 
studies need to take into consideration: i) longitudinal repeated measures to measure the Pace of 
Aging, ii) new statistical methods for estimating both Biological Age and the Pace of Aging, iii) 
young and old subjects, i.e. an age spectrum as wide as possible, iv) multiple biomarkers accounting 
for different organs and tissues of molecular and phenotypical nature. 
27. Motivation 
In this study, not only controls are used, but also prediabetics and diabetics. It can be noted that the 
inclusion of prediabetics and diabetics in the experiment does not fulfill the AFAR criteria for a 
biomarker to calculate the biological age, because “it must monitor a basic process that underlies 
the aging process, not the effects of disease”. Notwithstanding, many studies reflect that blood 
vessel damage, atherosclerosis, CVD and CVD-associated mortality affect a great majority of the 
elders (e.g. Yazdanyar and Newman, 2009). In accordance with this, Wang and Bennett (2012) 
recently proposed that “the effects of atherosclerosis are superimposed on normal aging of the 
underlying vessel”. We, therefore, considered a different strategy with regard to previous studies, 
that is, to test whether a mix biomarker that includes determinants of healthy and unhealthy aging 
(i.e. variables of atherosclerosis that overlap with aging) can estimate biological age, considering i) 
that pure controls do not exist and ii) that, in the elder population, the concept of healthy control is 
cumbersome, since when progressively approaching the age of the average life expectancy, even in 
absence of overt diseases, the likelihood that subclinical pathological processes are active is high. 
At the same time, the fact of not only considering controls, but also prediabetics and diabetics, 
increases the sample size, which, in turn, increases the power of the study. 
 
12. MATERIALS AND METHODS 
28. Materials 
The study used a total of 1146 individuals, comprising 177 Ctrl F, 108 Ctrl M, 185 PreDiab F, 121 
PreDiab M, 257 Diab F, and 298 Diab M. 39 phenotypical variables and 10 N-glycans were used, 
while HbA1c, Fasting Glucose, HOMA, and Insulin, which are variables that define the pre-T2D 
and T2D status, were excluded from the study, along with sex and age. The inclusion criteria 
considered individuals aged 20-85 years old, group- and sex-matched, and with an age balanced 
distribution among groups. 
29. Methods 
In this section, the methods utilized are as follows:  
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6. Univariate linear regression 
It determines the relationship between one independent variable (X) and one dependent variable 
(Y). It is handy when the relationship between 2 variables is not obvious to the naked eye. The 
disadvantage of univariate regression is that it leads to high bias error because the model is too 
simple (Oby Tayo, 2019). In this study, univariate regression models were used to test the 
association of age with each variable: Age ~ Variable. P-values were adjusted with Bonferroni 
correction for multiple testing at an α=0.05 and n=number of variables (n=55). 
7. Multiple linear regression 
It determines the relationship between several independent variables (X1 + X2 + Xj) and one 
dependent variable (Y). In this study, we tested the association of each phenotypical variable as 
function of sex, age and diabetes (Variable~Sex+Age+T2D status) in order to check for the partial 
effect of these 3 variables on the phenotypical variables.  
8. Penalization or shrinkage methods 
Unlike univariate regression, where there is high bias and low variance, multivariate regression 
models often have large variance, especially in situations of collinearity (note: the square of the bias 
and the variance are the 2 components of the MSE). In such models, the variance is large and the 
MSE is mainly determined by this variance. Penalization models impose a bias by applying a 
penalty to the regression coefficients (revised from Archarjee, 2013).  
1. Ridge regression 
It shrinks the regression coefficients by imposing a penalty on the sum of squares (L2 norm) of 
regression coefficients. In ridge, none of the estimated regression coefficients becomes exactly zero; 
therefore, all variables stay in the model (Archarjee, 2013).  
2. Lasso regression: 
It shrinks the regression coefficients by imposing a penalty on the sum of the absolute values of the 
regression coefficients (L1 norm) of regression coefficients. In LASSO, some of the estimated 
regression coefficients become exactly zero; therefore, only the selected variables stay in the model 
(Archarjee, 2013). 
3. Elastic net regression: 
It is a combination of ridge and LASSO because it shrinks the regression coefficients by imposing a 
penalty on the sum of squares (L2 norm) and a penalty on the sum of the absolute values of the 
regression coefficients (L1 norm) of regression coefficients (Archarjee, 2013). 
9. Machine learning methods: 
The goal of machine learning is to build a computer system that can learn from experience: 
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4. Random forest regression: 
It is made up of decision trees, each of which is built from bootstrap samples of the data set. In 
general, 2/3 parts of the samples (in this study 9/10) are used in the training set, and 1/3 (here 1/10) 
is left out (the so-called out-of-bag (OOB) samples). Variables used which decrease the prediction 
error obtain higher variable importance (Archarjee, 2013). 
5. Support vector regression: 
The goal of SVR is to find a function f(x)=wx+b that has at most ε deviation from the actually 
obtained response (Age) for all the predictors, and at the same time, minimizes the distance between 
predicted and observed values (Archarjee, 2013). 
10. Dimension-reduction methods: 
The goal is to transform the data from a high-dimensional space into a low-dimensional space, so 
that the latter retains meaningful properties of the original data:  
6. Principal component analysis (PCA):  
It is carried out on all original regressors, and each component (latent variable) is represented by a 
linear combination of the original variables (Archarjee, 2013). 
7. Two-way orthogonal partial least squares (O2PLS):  
See materials and methods of chapter 1. 
11. Klemera-Doubal method (KDM): 
Briefly, it takes information from m number of regression lines of chronological age regressed on m 
number of biomarkers (Klemera and Doubal, 2006). 
 
13. AIM  
As posed before, the research problem is based in that age is a risk factor for functional 
impairments, chronic diseases and mortality, and that the world’s population is aging at a fast speed, 
thus generating a major healthcare and socio-economic burden. Accordingly, the research questions 
to be addressed in this study are: 1) How can we better understand the underlying mechanisms of 
the aging process? 2) Which are the determinants of healthy and unhealthy aging? To shed light on 






30. Univariate regression models: Age ~ Variable  
First, to understand which variables may be importantly related to the Age variable, we conducted  
univariate models for all clinical variables and N-glycans (Table 20).  
Table 20. Univariate regression models. P-value was adjusted for multiple comparisons with Benjamini-
Hochberg correction at α=0.05 
Variable ß coefficient p-value adj. p-value Pearson cor (R2) 
GP2 0.01204 2.99E-46 1.58378E-44 0.404099 
GP6 -0.00659 3.37E-45 8.92652E-44 -0.3997 
EGFR -0.68998 2.92E-32 5.15406E-31 -0.33925 
GP1 0.008343 2.08E-29 2.75043E-28 0.323951 
WHR 0.002344 2.22E-26 2.34839E-25 0.306679 
Azotemia 0.006782 1.09E-21 9.65249E-21 0.277368 
HbA1c 0.030458 1.23E-18 9.32151E-18 0.256222 
GP3 -0.00573 9E-18 5.9604E-17 -0.24987 
GP4 -0.004 1.14E-17 6.70608E-17 -0.24911 
Fasting glucose 1.090439 1.88E-16 9.95026E-16 0.239809 
Alkaline phosphatase 0.005926 2.28E-13 1.09884E-12 0.214277 
Creatinine 0.004929 1.63E-12 7.21594E-12 0.206599 
Triglycerides 0.010435 2.38E-12 9.7003E-12 0.205099 
Fibrinogen 1.460053 9.37E-12 3.54891E-11 0.199527 
CRP 0.007166 5.7E-10 2.01502E-09 0.181771 
Uric acid 0.004198 6.1E-09 2.02152E-08 0.170667 
RDW-CV 0.000984 1.63E-08 5.0929E-08 0.165833 
Ferritin 0.003007 7.35E-08 2.16303E-07 0.158169 
Telomere length -0.00591 1.99E-07 5.55367E-07 -0.15288 
GP8 -0.00373 3.07E-06 8.14523E-06 -0.13732 
HOMA 0.003507 4.45E-06 1.12292E-05 0.13509 
Lymphocytes -0.00333 0.000147 0.000355207 -0.11188 
Transferrin -0.44121 0.000163 0.000376039 -0.11114 
GGT 0.003923 0.000334 0.000736812 0.105797 
MCV 0.049961 0.000459 0.000973306 0.10333 
GP10 -0.00326 0.000527 0.001074489 -0.10225 
BMI 0.040743 0.001718 0.00337147 0.092515 
Apo B 0.223262 0.002726 0.005159625 0.088456 
Red cells -0.00346 0.003931 0.007184274 -0.08512 
GP9 0.003783 0.004745 0.008383449 0.083361 
MPV 0.006914 0.007817 0.013364789 0.078536 
GP5 -0.00102 0.014079 0.023318579 -0.07251 
Hemoglobin -0.0085 0.015148 0.024328113 -0.07173 
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Cholesterol 0.227759 0.027009 0.042102768 0.065325 
HDL -0.08464 0.035829 0.054255352 -0.06201 
Neutrophils 0.001929 0.045682 0.067254532 0.059043 
ALT -0.00149 0.052744 0.07555229 -0.05723 
Platelets -0.30588 0.058009 0.080906828 -0.05601 
Eosinophils 0.002526 0.071087 0.09660524 0.053337 
AST 0.001594 0.084948 0.109811313 0.05091 
SDMA -0.00126 0.083844 0.109811313 -0.05109 
Total bilirubin 0.001185 0.147456 0.186074961 0.042818 
PAI 0.032517 0.265923 0.327765146 0.03289 
LDL 0.081479 0.342078 0.412048548 0.02809 
Total protein 0.001047 0.43205 0.508859405 0.023231 
TAFI 0.034632 0.490267 0.564872475 0.020399 
Monocytes 0.000538 0.501263 0.565253754 0.019885 
White cells -0.00273 0.530401 0.573699376 -0.01855 
ADMA 0.000446 0.521458 0.573699376 0.018957 
Apo A1 -0.0527 0.554935 0.588230573 -0.01746 
Insulin 0.000512 0.757608 0.787317775 0.009126 
GP7 0.00016 0.81052 0.826106591 0.00709 
Total iron -0.00044 0.995338 0.995338448 -0.00017 
 
Table 20 shows that variables most significantly correlated with age (R2≥0.1, p<0.05) are GP2, 
GP6, EGFR, GP1, WHR, Azotemia, HbA1c, GP3, GP4, Fasting glucose, Alkaline Phosphatase, 
Creatinine, Triglycerides, Fibrinogen, CRP, Uric Acid, RDW-CVM, Ferritin, Telomere Length, 
GP8, HOMA, Lymphocytes, Transferrin, GGT, MCV, GP10; and variables with larger effect sizes 
are Fibrinogen (ß=1.46), Fasting glucose (ß=1.09), EGFR (ß=-0.69) and Transferrin (ß=-0.44).  
31. Statistical models 
Firstly, different statistical methods were tested, one based on a score, and five other methods based 
on 49 standardized predictors (39 phenotypical, 10 N-glycans). 
12. Biological Age I: Score-Based 
On the one hand, 7 O2PLS models were conducted, in which we integrated Glycomics (10 
variables) with Phenomics (39), Lipids (8), Liver (8), Kidney (8), Iron (3), Coagulation (3), and 
Blood (8). For each model, the number of joint and specific PCs were estimated with cross-
validation. Then, the 46 PCs obtained in the 7 models were regressed to chronological age using an 
elastic net model, which selected 34 PCs. 
On the other hand, a PCA was performed on the 49 predictors. Then, they were regressed to 




13. Biological Age II: Based on 49 predictors 
Secondly, three penalized models were employed, namely ridge regression (RR), lasso (LASSO), 
and elastic net (EN), and two machine learning algorithms, that is random forest (RF) and support 
vector machine (SVM). Each one of the regression models were applied on 49 independent 
variables and Age as response variable on the training set (using 9/10 folds). For that, a grid search 
was used to estimate the hyperparameters of the model with cross-validation (Table 21), using 
glmnet and caret packages from R. The models were computed using the hyperparameters and 
compared through metrics of performance (Table 22). 











Overall, the models did not generalize well (they were fitted to non-predictive noise in the training 
set), specially the machine learning algorithms RF and SVM, which overfit, as evidenced by the 
high R2 in the training set and the low R2 (low accuracy) in the test set. The methods that best 
performed were O2PLS+EN and PCA+EN, specially the former displays the highest accuracy and 
lowest error in the test set; therefore, the two of them were chosen over the other methods for the 
downstream analysis. 
Table 22. Metrics of model performance 
Method Metrics of model performance 
R2 training set R2 test set MSEP test set 
O2PLS+EN 0.44 0.31 93.85 
PCA+EN 0.52 0.17 35662.2 
RR 0.50 0.08 25535.62 
LASSO 0.52 0.07 47782.64 
EN 0.54 0.07 49126.24 
RF 0.96 0.20 134.62 
SVM 0.74 #N/D (sd=0) 842.20 
 
Algorithm Hyperparameters 
O2PLS EN α=0.9 
λ(1SD)=0 
















32. Association between “Biological Age” and “Chronological Age”, separately in 
sexes:  
Thirdly, the association between the biological ages obtained with elastic net of O2PLS and elastic 
net of PCA (the models displaying the best performances) and chronological age was tested, and the 
KDM on them. Additionally, to have a control, the KDM was applied on the original 49 predictor 
variables. Eventually, the association between biological and chronological ages of the 3 KDM 
models (i.e. O2PLS+EN+KDM; PCA+EN+KDM; KDM) was compared with the O2PLS+EN and 
PCA+EN models. The association was tested separately in males and females and separately in 
groups (Table 23). In the three groups (controls, prediabetics, and diabetics), the raw KDM on the 
49 predictors best predicted chronological age; thus, KDM was taken for the downstream analysis. 
Table 23. Summary output of the linear model: Predicted Age = Biological Age ~ Chronological Age 
  
Group Model Sex beta p-value R2 
Controls O2PLS+EN Female 0.49 <2e-16 0.58 
Male 0.38 5.318e-14 0.44 
PCA+EN Female 0.56 <2e-16 0.65 
Male 0.47 6.84e-16 0.49 
KDM Female 1.07 <2e-16 0.80 
Male 0.87 <2e-16 0.68 
O2PLS+EN+KDM Female 1.11 <2e-16 0.70 
Male 0.83 <2e-16 0.56 
PCA+EN+KDM Female 1.53 2.67e-07 0.15 
Male 0.76 0.07309 0.03 
Prediabetics O2PLS+EN Female 0.44 <2e-16 0.44 
Male 0.42 6.38e-14 0.42 
PCA+EN Female 0.53 <2e-16 0.58 
Male 0.47 <2e-16 0.48 
KDM Female 1.03 <2e-16 0.73 
Male 0.91 <2e-16 0.70 
O2PLS+EN+KDM Female 1.07 <2e-16 0.62 
Male 0.83 <2e-16 0.53 
PCA+EN+KDM Female 1.20 0.0001 0.08 
Male 0.75 0.07694 0.02 
Diabetics O2PLS+EN Female 0.32 3.855e-10 0.16 
Male 0.32 2.264e-15 0.21 
PCA+EN Female 0.38 3.701e-16 0.25 
Male 0.38 <2e-16 0.30 
KDM Female 0.81 <2e-16 0.40 
Male 0.82 <2e-16 0.48 
O2PLS+EN+KDM Female 0.69 1.416e-13 0.21 
Male 0.69 <2e-16 0.28 
PCA+EN+KDM Female 1.19 0.0001082 0.08 
Male 0.75 0.076 0.02 
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33. Association between “Biological Age” with disease (T2D) separately in sexes:  
A multinomial logistic model was calculated to test the association of the Biological Age with T2D. 
Ctrl was the reference group to which “PreDiab” and “Diab” levels were compared in each sex 
(Table 24). 
The models output indicates that Biological Age of the KDM can significantly discriminate Ctrl F 
from PreDiab F and Diab F, and Ctrl M from PreDiab M and Diab M. 






1. Age acceleration in respect to controls calculated for both prediabetics and diabetics, 
separately in males and females, using the training data 
 
Figure 74. Age acceleration among controls, prediabetics, and diabetics in both sexes 
In order to establish whether prediabetics and diabetics had an accelerated aging compared with 
controls, the delta age (also called Age Acceleration (AgeAccel)) was estimated by calculating the 
difference between “Biological Age” and “Predicted Age” (defined as the association between 
“Biological Age” and chronological age) and plotted (Figure 74). The mean values were as 
follows: 0 Ctrl F, 0 Ctrl M, 1.97 PreDiab F, 1.67 PreDiab M, 3.79 Diab F, 3.25 Diab M.  
Pairwise comparisons using Wilcoxon’s rank sum test revealed no statistical differences between 
sexes in controls, prediabetics and diabetics (Table 25). It is interesting to note that, while control 
females show a younger trend than control males, this trend is reversed in prediabetics and 
Model Group OR  p-value CI (95%) 
KDM Diab F 1.09 5.71e-19 1.07-1.12 
PreDiab F 1.03 3.60e-4  1.01-1.05 
Diab M 1.10 5.45e-14 1.07-1.13 
PreDiab M 1.05  1.02e-3 1.02-1.07 
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diabetics, so that despite there are no statistical differences, females are slightly biologically older 
than males, as the above-mentioned means highlight. It can also be observed that there are statistical 
differences, though small, between prediabetic females and control females and males, while 
prediabetic males showed no differences with controls.  
Table 25. Pairwise comparisons using Wilcoxon’s rank sum test in KDM. P-value adjustment method: 
Benjamini-Hochberg. P<0.05 (*), p<0.01 (**), p<0.001 (***) at α=0.05. 
34. Associations with continuous traits or N-glycans: Trait/N-glycan ~ 
Phenotypical Age + Age + Sex + Group 
Finally, we aimed to measure the association between continuous clinical traits or N-glycans with 
Biological Age, Age, Sex, and Group with multiple linear regression. Beta values and p-values for 
N-glycans and clinical traits are shown in Table 26 and Table 27. It can be noted that only GP1, 
monocytes and RDW-CV were significantly associated with biological age, independently of 
chronological age, sex and disease status (p=0, 0.007, 5.31E-07, respectively). No variables were 
significantly associated with disease status independently of biological and chronological ages and 
sex. Platelets and Lymphocytes were significantly associated with Sex, independently of biological 
and chronological ages and disease status (p=1.37E-36 and 1.69E-17, respectively). No variables 
were significantly associated with chronological age, independently of biological age, sex and 
disease status. 
Table 26. Association between continuous N-glycans species and Biological Age, Chronological Age, Sex 
and Disease Status: Trait ~ Biological Age + Chronological Age + Disease Status 
 
 Ctrl F Ctrl M  PreDiab F  PreDiab M Diab F 
Ctrl M 0.95     
PreDiab F 0.03(*) 0.04 (*)    
PreDiab M 0.06 0.08 0.67   
Diab F 5.3e-05 (***) 0.0002 (***) 0.08 0.036 (*)  

















GP1 1 0 -9.2E-17 0.159165 3.96E-16 0.62077 5.91E-16 0.263415 
GP2 1.72E-17 2.61E-10 5.02E-18 0.116252 1.68E-16 2.03E-05 1 0 
GP3 6.8E-16 9.4E-124 1 0 2.64E-16 0.467184 3.94E-16 0.09964 
GP4 0.016255 3.46E-49 -0.00679 5.04E-08 -0.0095 0.532243 -0.03354 0.000852 
GP5 0.021727 1.67E-73 -0.00992 6.89E-14 -0.05735 0.000374 0.012241 0.247958 
GP6 -0.00938 2.32E-21 0.005436 2.32E-06 0.06289 8.88E-06 -0.07249 1.42E-14 
GP7 -0.00789 6.48E-29 0.004164 3.42E-07 0.056447 2.04E-08 -0.01538 0.019611 
GP8 -0.00529 7.16E-16 0.003622 2.43E-06 -0.00042 0.964004 0.034274 4.07E-08 
GP9 -0.01466 5.8E-117 0.007028 3.19E-25 0.057524 2.53E-12 0.027785 2.48E-07 
GP10 -0.00812 2.38E-14 0.007481 2.31E-09 0.000314 0.983589 0.01116 0.267888 
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Table 27. Association between continuous clinical traits and Biological Age, Chronological Age, Sex and 

















BMI -0.00255 0.036798 -0.00178 0.215943 -0.18477 3.23E-24 0.036119 0.002062 
WHR 0.012832 2.98E-10 -0.0091 0.000147 0.288206 8.78E-22 -0.02197 0.256802 
Fasting Glucose -0.00293 0.041663 -0.00015 0.930601 -0.21333 2.21E-23 0.021797 0.113734 
HbA1c 0.193287 1.84E-22 -0.18753 8.05E-16 -0.55755 0.048287 0.929867 6.64E-07 
Total Cholesterol 0.003127 6.3E-30 -0.00126 7.2E-05 0.074678 1.13E-70 0.015053 5.42E-09 
HDL 0.665669 2.5E-05 -0.65931 0.000413 3.521481 0.124387 38.97394 1.1E-113 
EGFR 0.014592 0.000471 -0.01388 0.004892 -0.10381 0.086912 1.061765 6.3E-119 
Fibrinogen 0.66555 3.58E-05 -0.27081 0.153788 -18.7322 2.82E-15 -5.27745 0.00063 
PAI1 -0.47351 1.11E-15 0.438241 2.88E-10 -8.99828 4.35E-25 -1.64194 0.003341 
TAFI -1.40451 6.09E-63 0.694136 1.36E-13 7.794943 1.31E-11 -1.17456 0.117929 
Total Bilirubin 3.836766 5.52E-32 -2.33836 5.18E-10 -31.6828 8.65E-12 2.431957 0.421341 
LDL 0.15311 0.000843 -0.09494 0.07966 0.10186 0.878472 -1.03515 0.018553 
Apo A1 0.393555 5.62E-07 -0.26769 0.003881 -5.00611 1.21E-05 -2.54188 0.000731 
Apo B -0.00586 3.67E-06 0.007381 8.49E-07 0.149039 1.24E-15 -0.03338 0.005847 
Total Iron 0.295841 0.029586 -0.10339 0.52012 -9.25305 3.27E-06 -4.33327 0.000918 
Transferrin -0.65591 1.45E-06 0.715181 8.89E-06 -18.1319 1.97E-19 -3.94606 0.002448 
Total Protein 0.617433 2.45E-07 -0.39015 0.005629 -4.40632 0.011037 -0.54345 0.633859 
White Cells -0.4812 6.42E-05 0.402626 0.004638 6.573219 0.000177 1.36713 0.235204 
Red Cells -0.85973 2.72E-06 0.162311 0.451898 -3.44471 0.194664 7.921404 6.66E-06 
Hemoglobin 0.00825 9.28E-05 -0.00806 0.00123 0.085982 0.005079 0.017416 0.388358 
MCV 0.043556 2.11E-10 -0.0547 1.66E-11 -0.00165 0.986661 0.292566 7.92E-06 
Platelets -0.00338 0.060643 -0.00068 0.749749 0.344655 1.37E-36 -0.00544 0.752802 
MPV -0.01324 0.005447 0.00132 0.814402 1.386223 1.37E-75 0.074143 0.104381 
Neutrophils 0.01328 0.557997 0.05391 0.044669 0.619151 0.060944 -0.4569 0.035945 
Lymphocytes 0.041548 0.866223 -0.1939 0.506538 -31.1282 1.69E-17 -2.1346 0.367369 
Eosinophils 0.004856 0.242841 0.002843 0.563229 0.059328 0.327139 -0.03846 0.335169 
Monocytes 0.004172 0.007286 -0.00269 0.142703 -0.0217 0.33705 0.010162 0.495213 
Creatinine -0.00538 9.37E-05 0.002004 0.21718 -0.07518 0.000177 -0.00078 0.95251 
AST 0.0007 0.75515 0.000777 0.769745 0.059802 0.067417 0.029153 0.175994 
HOMA -0.00047 0.713474 0.002689 0.074996 0.067154 0.000312 -0.05542 6.62E-06 
ALT 0.016365 1.35E-69 -0.01139 1.32E-27 0.178272 3.21E-42 0.008913 0.27968 
Triglycerides 0.004887 0.00064 -0.00214 0.205616 0.089646 1.76E-05 -0.05405 8.49E-05 
Insulin 0.009862 5.77E-19 -0.01012 9.25E-15 -0.00753 0.634585 0.118851 2.18E-28 
CRP 0.003668 0.001948 -0.00718 3.31E-07 0.07932 4.49E-06 0.050828 8.15E-06 
GGT 0.030034 3.74E-42 -0.02223 2.28E-18 0.023936 0.435827 0.094908 3.11E-06 
Ferritin 0.021727 1.11E-16 -0.023 9.94E-14 -0.04607 0.219681 0.019387 0.433187 
Alkaline Phosphatase 0.025082 1.27E-50 -0.01801 5.82E-21 -0.11135 1.63E-06 0.007909 0.603337 
Azotemia 0.012378 7.71E-13 -0.00951 2.77E-06 0.080524 0.001225 0.024529 0.134333 
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Uric Acid 0.005185 3.64E-10 -0.00272 0.00516 0.11699 9.12E-22 0.01544 0.049822 
Telomere Length 0.014925 4.11E-33 -0.00833 6.35E-09 -0.07923 6.65E-06 -0.02107 0.067996 
SDMA 0.011547 2.13E-26 -0.00393 0.001714 0.033996 0.02731 -0.02745 0.00688 
ADMA 0.013767 4.69E-39 -0.00948 5.35E-15 0.137505 5.12E-20 -0.0137 0.157582 




The increase in geriatric population around the globe highlights the need for better understanding 
the processes underlying healthy and unhealthy aging, as age is a major risk factor for functional 
impairments, chronic diseases and mortality. In this context, the biomarkers of aging have come 
into play. There are two main ways of estimating biological age: 1) the traditional estimation of 
mortality curves (Moskalev, 2020) and 2) the estimation of chronological age (Horvath, 2013). The 
former has the disadvantage that it cannot be used to measure functional decline, predict morbidity 
onset and life expectancy, while the latter evidences the unsolved “paradox of biomarkers”, which 
uses a set of biological predictors to predict chronological age with linear regression, therefore 
resulting in biological age equal to chronological age (Hochschild, 1994). In addition, so far none of 
the studies carried out with the goal of defining new biomarkers of age has fulfilled the AFAR 
criteria (Johnson, 2006).  
In this study, we made use of a novel approach: 39 clinical predictors and 10 N-glycans were used 
as biological predictors for chronological age, considering three groups of individuals, that is, 
controls, prediabetics, and diabetics, and both sexes. We tested different models, and the Klemera-
Doubal one was the best in terms of performance. We applied this method on the 49 predictors, 
from which we derived our “biological age”. The calculated biological age was then associated with 
chronological age, T2D status, and with continuous clinical and N-glycan traits. Eventually, age 
acceleration was computed for each one of the six groups. Results showed that biological age was 
significantly associated with chronological age in the three groups in both sexes, that biological age 
can significantly predict (non-)prediabetic and (non-)diabetic status, and that biological age is 
significantly associated with GP1, monocytes and RDW-CV, independently of chronological age, 
sex and (non-)pre-/T2D status. Furthermore, results confirmed that prediabetic females are 
significantly older than control males and control females, and that diabetics are not significantly 
different than prediabetics, but they are significantly biologically older than controls, in both sexes.  
Summarizing, we have identified the biological age in individuals with diverse phenotypes, that is, 
healthy, dysmetabolic, prediabetic, and diabetic, by using the chronological ages and clinical and N-
glycan predictors in all of them at once, therefore without fulfilling the AFAR criterium by which a 
biomarker of age “must monitor a basic process that underlies the aging process, not the effects of 
disease”. The underlying reason for such design is that controls, with age, become inevitably less 
healthy, and especially around 60 years of age and above, it is difficult to find totally healthy 
controls, or, in other words, without subclinical or clinical symptoms of age-related diseases. 
Indeed, at least two review articles support this hypothesis. The first, from Wang and Bennett 
(2012), who stated that “the effects of atherosclerosis are superimposed on normal aging of the 
underlying vessel”. The second, from Franceschi et al. (2018), claims that precise boundaries 
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between aging and age-related diseases or geriatric syndromes do not exist, but instead they are a 
continuum.  
Unfortunately, our design makes it incomparable with findings of previous studies. Besides, most of 
the aging biomarkers identified are epigenetic clocks (Jylhävä et al., 2017). Nonetheless, at least 
two previous studies also estimated a composite-based biomarker of age, and another one who 
estimated a glycomics-based biomarker. Levine (2013) focused on the methodology and compared 
different statistical methods, reaching the conclusion that KDM was the best, the same that in our 
study, though here we compared other statistical methods. In turn, Belsky et al. (2015) used 10 
biomarkers for estimating biological age (Glycated haemoglobin, Forced expiratory volume in one 
second (FEV1), Blood pressure (systolic), Total cholesterol, C-reactive protein, Creatinine, Urea 
nitrogen, Albumin, Alkaline phosphatase, and Cytomegalovirus IgG.) of each Dunedin Study 
member’s at age 38, that is, 7 of our 49 variables, with the KDM, and one of the conclusions they 
draw is that biological age can provide a summary of accumulated aging in cases when only cross-
sectional data are available (Belsky et al. (2015)), a conclusion that we also draw in our study. 
Eventually, Krištić et al. (2014) used 24 UPLC N-glycans and estimated both chronological and 
biological ages by building predictive models. They demonstrated that 3 N-glycans (FA2B, FA2G2, 
FA2BG2, which correspond to GP2, GP6, and GP7 in DSA-FACE glycans, respectively) changed 
considerably with age; from these, GP2 and GP6 are the top 2 out of 49 variables most significantly 
associated with chronological age (Table 20) and biological age (Table 27), while GP7, in our 
study, has a Pearson’s correlation of 0.007 and p=0.8 (Table 20). 
Together, our findings constitute proof of principle for the measures of biological age in individuals 
with age-related diseases. Here we identify several future directions that can build on this proof-of-
principle for estimating accelerated age from younger to older ages. 
First, our analysis was limited to a single cohort, and one that lacked ethnic minority populations. 
Replication in other cohorts is needed, and replication using a larger number of younger and older 
healthy controls, younger and older less healthy controls, prediabetics and diabetics can also 
provide additional perspectives. Larger samples can also help understanding the less common 
phenotypes.  
Second, DSA-FACE N-glycans are low-dimensional and have the disadvantage that sialic acids are 
cut-off from the sugar, which blurs the interpretation of results. Further studies are needed that use 
N-glycans obtained with other technologies which include sialic acids and produce more N-glycan 
species, and not only from whole plasma glycome, but also from IgG glycome, which is especially 
relevant for understanding the role of inflamm-aging and metaflammation played by N-glycans. 
Third, the nature of the cross-sectional makes available just a snapshot of the phenotype. Therefore, 
further studies comprising multiple biomarkers sampled at different points of time are required to 
measure the pace of aging, since summarizing the data obtained at one single point cannot measure 
the functional decline nor predict the morbidity onset and life expectancy.  
Within the bounds of these limitations, the implication of the present work is that it is possible to 
identify a composite based biomarker of aging that not only considers pure healthy controls, but 






In this thesis, we aimed to conduct an in-depth analysis of metabolic phenotype by studying age- 
and sex-related features of type 2 diabetes. On the one hand, it was first tested whether 10 N-
glycans could predict better the diabetic status than HbA1c, and results showed that N-glycans 
cannot compete with the gold standard HbA1c. Secondly, an extensive characterization of the 
T2D/(dys)metabolic/aging phenotype was performed. Based on the integration of a set or subsets 
(part I and part II, respectively) of 44 clinical variables and 10 N-glycans, it can be concluded that:  
i. N-glycans GP3, GP4, GP6 are negatively associated with age in the three groups of 
individuals, that is controls, prediabetics, and diabetics, in both sexes. 
ii. N-glycans GP8 and GP10 are positively associated with a metabolism dysregulation, as 
revealed by prediabetic males and diabetics. 
iii. The observed N-glycans in control males are mainly correlated with coagulation and blood 
parameters; in control and prediabetic females, with age, alkaline phosphatase and lipid 
parameters; in prediabetic males, with coagulation parameters; and in diabetics, with 
diverse parameters from the phenomics data set, including lipid, coagulation, iron, blood 
parameters and factors used for the T2D diagnosis. 
iv. The decreasing intra-correlations between pairs of joint PCs from controls (R2=0.7%), 
prediabetics (R2=0.6%), and diabetics (R2=0.5%) in the integration phenomics/glycomics 
(part I) underlines the heterogeneity and/or complexity of disease and age, or, in other 
words, the higher homogeneity of controls. 
v. Males and females present different biological dynamics, as noted by the biochemical and 
glycomics data, especially at 20-44 and at 45-55 years of age, while at 56-70 and 71-85 
tend to progressively converge. 
vi. Control, prediabetic, and diabetic individuals, generally, present different quantities of 
biochemical and glycomics parameters. 
vii. Inter-correlations between individual joint PCs scores (part II) show that in prediabetics and 
diabetics N-glycans are generally the same when integrated with different endophenotypes, 
instead of revealing a specific signature for each endophenotype. 
On the other hand, we computed a composite biomarker of aging, by building on a predictive model 
of chronological age composed of 49 predictors, based on the Klemera-Doubal method. Over recent 
years, this method has become increasingly popular for measuring biological age. In this study, this 
approach was used on 1146 individuals, including controls, prediabetics, and diabetics of both 
sexes. On the whole, it demonstrated that biological age: a) is significantly associated with 
chronological age in the three groups in both sexes, b) can significantly predict (non-)prediabetic 
and (non-)diabetic status, c) is significantly associated with GP1, monocytes and RDW-CV, 
independently of chronological age, sex and (non-)pre-/T2D status. In addition, age acceleration, 
computed as the difference between biological age and predicted age, confirmed that prediabetic 
females are significantly older than control males and control females, and that diabetics are not 
significantly different than prediabetics, but they are significantly biologically older than controls, 
in both sexes. 
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Based on these conclusions, to better understand the implications of these results, future studies 
should include longitudinal sampling of clinical parameters and N-glycans species, glycomics 
technologies that are higher dimensional and that include sialic acids, larger cohorts, and cohorts of 
ethnic minorities. In particular, repetitive measures as well as mortality data could contribute to 
answer the question of whether N-glycans change over the course of preclinical (that is, insulin 
resistance and impaired insulin secretion) to clinical diagnoses (obesity and/or T2D, T2D 
complications, metabolic syndrome). Further research will be needed to address this question. 
It is important to emphasize that this work has provided a deeper understanding of N-glycan 
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